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Abstract 
Ellis, Amanda Lynne (Ph.D., Psychology and Neuroscience) 
Glial Mechanisms of Central Neuropathic Pain 
Thesis directed by Distinguished Professor Linda Watkins 
 
 Neuropathic pain is a debilitating condition that is usually intractable to treatment. Spinal 
cord injury (SCI) is the leading cause of central neuropathic pain (CNP), and patients often 
describe their pain as severe and intolerable. Although most of the focus in the pain literature has 
been on neurons, it is now well known that non-neuronal cells of the central nervous system 
called microglia and astrocytes (herein referred to as “glial cells” or “glia”) play a key role in the 
induction and maintenance of neuropathic pain. Glia are immune cells that are normally in a 
surveying/quiescent state, but upon activation by an inflammatory stimulus, they release a host 
of proinflammatory mediators that can sustain neuropathic pain for weeks, months, and even 
years. Interestingly, glia can also release anti-inflammatory mediators, making them ideal for 
therapeutic targeting. The glial mechanisms underlying CNP have not been fully explored and 
understood, and Chapter II is a set of studies undertaken to determine the involvement of glia in 
a novel rat model of thoracic-13/lumbar-1 (T13/L1) dorsal root avulsion SCI termed Spinal 
Neuropathic Avulsion Pain (SNAP). SNAP induced a robust, reliable, long-lasting below-level 
hind paw allodynia that was reversed by 3 different glial activation inhibitors. These studies 
confirmed that glia are involved in the mechanism underlying SNAP and that use of therapies 
that target glial cells could provide a better route for treating CNP. The studies in Chapter III 
determined that CNP could be attenuated by a single injection of an adenosine A2A receptor 
agonist for at least 6 weeks. This attenuation is due to a decrease in glial activation and 
proinflammatory cytokine expression, and at least in part dependent on the anti-inflammatory 
cytokine IL-10. The studies in Chapter IV detail a phenomenon in which administering opioids 
iv 
 
shortly after SNAP increases the magnitude of allodynia and potentiates the expression of 
proinflammatory mediators. This mechanism is at least in part dependent on toll-like receptor 4 
and the proinflammatory cytokine IL-1β. The evidence from this dissertation suggests that glial 
cells are critically involved in the mechanisms underlying CNP, and that they can be 
manipulated to attenuate or potentiate CNP depending on their microenvironment and pattern of 
receptor activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
Dedication 
 
This dissertation is dedicated to my true love, soul mate, and husband Shane 
Michael, my other half and beautiful sister Anjelica “Jeli” Ellis, my wonderful 
parents Ben and Jeanne Ellis, my amazing grandma Jeannette Veltrie, my furry 
four legged children Shelby and Iacocca (Cocca), and to all the rats, especially 
Sneezy.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
Acknowledgments 
 
I would first like to thank my mentors Linda Watkins and Steve Maier. I 
am honored to have been a graduate student under you, and I couldn’t 
imagine having a better mentor. Linda, you have taught me so much and 
push me to be a better scientist every day. You care about me not just as a 
scientist, but as a person, and I will be forever grateful to have been a part 
of your lab. 
 
Thank you to my committee: Linda, Steve, Serge, Ben, and Mike for taking 
the time out of your busy lives and schedules to mentor me through this 
process. 
 
I would like to also thank my post-doc mentors Lisa Loram, Khara Ramos, 
Peter Grace, and especially Julie Wieseler. 
 
I must of course give a shout out to all my fellow grad students and lab 
mates who have been on this journey with me, especially my office mate 
Mike Weber who had to put up with everything from me buying a house, 
getting married, and writing my dissertation, and “Friend” Alexis 
Northcutt without whom there is NO WAY I would have gotten through 
grad school without. 
 
Last but not least I want to thank my husband and family. You have all 
been there with me from the beginning and have whole-heartedly 
supported me and showered me with love. There was never any doubt in 
my mind that I could do this because you all told me I could! I love you so 
very much Shane, Jeli, Mom, Dad, and Grammy Bear!  
 
 
vii 
 
Table of Contents 
 
Title Page .......................................................................................................................................... i 
Signature Page ................................................................................................................................. ii 
Abstract........................................................................................................................................... iii  
Dedication ........................................................................................................................................ v  
Acknowledgements  ....................................................................................................................... vi 
List of Tables ................................................................................................................................... ix 
List of Figures ................................................................................................................................... x 
 
Chapter I: Introduction .................................................................................................................... 1 
Preface ................................................................................................................................................. 1 
The Role of Glia in Pain Processing ............................................................................................. 4 
Non-pathological pain processing ...................................................................................... 4 
Pathological pain processing in neurons and glia ............................................................... 5 
Similarities and differences between peripheral and central neuropathic pain ................. 8 
Glial activation in central neuropathy ................................................................................ 9 
Glial activation and inflammation in spinal cord injury (SCI)  ............................................. 9 
Targeting glia for treating central neuropathic pain ........................................................ 11 
Glia and Adenosine Signaling .................................................................................................... 14 
Adenosine signaling .......................................................................................................... 14 
Role of A2AR in SCI ............................................................................................................. 16 
IL-10 and alternative activation ........................................................................................ 16 
Glia and the Immune System ..................................................................................................... 19 
Glia as immune cells ......................................................................................................... 19 
TLR4 signaling ................................................................................................................... 20 
Cytokine processing and inflammasomes ......................................................................... 22 
Theoretical Considerations and Thesis Overview .................................................................... 24 
 
Chapter II: Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each 
Reverses Mechanical Allodynia in Novel Rat Model of Central Neuropathic Pain ....................... 28 
Abstract .......................................................................................................................................... 28 
Introduction ................................................................................................................................... 29 
viii 
 
Materials and Methods .................................................................................................................. 30 
Results ............................................................................................................................................ 36 
Discussion ....................................................................................................................................... 48 
Chapter III: Sustained Reversal of Central Neuropathic Pain Induced by a Single Intrathecal 
Injection of Adenosine A2A Receptor Agonists .............................................................................. 54 
Abstract .......................................................................................................................................... 54 
Introduction ................................................................................................................................... 56 
Materials and Methods .................................................................................................................. 58 
Results ............................................................................................................................................ 64 
Discussion ....................................................................................................................................... 73 
 
Chapter IV: Morphine Amplification of Central Neuropathic Pain and Neuroinflammation in a 
Rat Model of Spinal Cord Injury ..................................................................................................... 78 
Abstract .......................................................................................................................................... 78 
Introduction ................................................................................................................................... 79 
Materials and Methods .................................................................................................................. 80 
Results ............................................................................................................................................ 88 
Discussion ....................................................................................................................................... 97 
 
Chapter V: General Discussion .................................................................................................... 102 
 
 Summary of main experimental results........................................................................... 102 
The clinical utility of administering glial activation inhibitors for CNP ............................ 108 
 
References ................................................................................................................................... 114 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Tables 
Chapter III: 
Table 3.1: List of RT-PCR primers 
Chapter IV: 
Table 4.1: List of RT-PCR primers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
Chapter II: 
 Figure 2.1: Effect of administering propentofylline on SNAP 
 Figure 2.2: Detailed timecourse of administering propentofylline on SNAP 
 Figure 2.3: Effect of administering ibudilast late in the development of SNAP 
 Figure 2.4: Effect of administering ibudilast early in the development of SNAP 
 Figure 2.5: Effect of administering (+)-naltrexone on SNAP 
 Figure 2.6: Effect of ceasing (+)-naltrexone administration on SNAP  
 
 
Chapter III: 
 Figure 3.1: Effect of administering the A2AR agonist CGS21680 on SNAP 
Figure 3.2: Effect of administering neutralizing IL-10 antibodies on the CGS21680 
effect in SNAP  
Figure 3.3: Effect of administering the A2AR agonist CGS21680 on mRNA gene 
expression 
Figure 3.4: Effect of administering the A2AR agonist ATL313 on SNAP 
 
 
Chapter IV: 
 
  
Figure 4.1: Effect of administering a week-long course of morphine beginning 24 hr 
post-surgery on SNAP 
Figure 4.2: Effect of administering a week-long course of morphine beginning 24 hr 
post-surgery on glial activation marker mRNA gene expression 
Figure 4.3: Effect of administering a week-long course of morphine beginning 24 hr 
post-surgery on TLR4 and TNF-α mRNA gene expression 
Figure 4.4: Effect of co-administering a week-long course of morphine and the TLR4 
antagonist (+)-naltrexone beginning 24 hr post-surgery on SNAP 
Figure 4.5: Effect of administering a week-long course of morphine beginning 24 hr 
post-surgery on IL-1β and NLRP3 inflammasome mRNA gene expression and protein 
  
 
 
 
1 
 
Chapter I 
Introduction 
 Preface 
One of the most dynamic sensory systems in the body is pain. Pain in a normal, healthy 
sensory system is important as it is both protective and adaptive; pain is a warning signal to get 
you out of danger and begin the healing process. It is when you have a dysregulation of this 
system that pain becomes pathological. Acute, non-pathological pain activates peripheral nerve 
endings called nociceptors, which send signals to the dorsal horn of the spinal cord that are 
relayed all the way up to the cortex. This pain is referred to as “nociceptive pain”.54 However, 
when neural tissue of the central nervous system (CNS) becomes damaged, a form of 
pathological pain referred to as central neuropathic pain can occur.
208
 Such neuropathic pain is 
characterized by a sensory deficit, a burning sensation, widespread pain extending beyond the 
area of original injury, pain caused by light touch (allodynia), or spontaneous pain in the absence 
of noxious stimuli.
36
 Central neuropathic pain can last for months or even years, and arises in a 
variety of CNS disorders including spinal cord injury (SCI), traumatic brain injury (TBI), 
multiple sclerosis (MS), stroke, and Parkinson’s disease. Unfortunately, this type of pain is often 
severe and intolerable and is intractable to treatment. There is an urgent need to develop more 
efficacious therapeutics in order to help the millions of people that suffer from chronic pain 
disorders.  
 Our understanding of pathological pain has previously centered on neuronal 
mechanisms. However, it is now accepted that glial cells, here referred to as microglia and 
astrocytes, are important pain modulators and contribute to both the induction and maintenance 
of neuropathic pain, including central neuropathic pain.
326
 Glia are the non-neuronal immune-
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like cells of the CNS and constitute nearly 70% of the total cell population in the brain and spinal 
cord.
211
 There are several subtypes of glia, including microglia, astrocytes, and oligodendrocytes. 
Although they all have some overlap in function, they play different roles in pain processing. For 
this dissertation, only microglia and astrocytes will be discussed.  
Microglia only make up 5-10% of the total glial population and are split into two 
subtypes, resident microglia and perivascular microglia. Resident microglia are bone-marrow or 
yolk sac derived hematopoietic cells that migrate to the CNS during embryonic or early post-
natal development, and are never replenished.
129
 Perivascular microglia are derived from bone-
marrow precursors in adulthood and are continuously replenished, especially after peripheral 
nerve damage and CNS inflammation.
129, 176, 362
 Resident microglia have long processes that are 
constantly surveying their environment and upon activation can exert both pro- and anti-
inflammatory effects. Perivascular microglia can alter the blood brain barrier (BBB) and both 
resident and perivascular microglia can produce proinflammatory mediators upon activation that 
can go on to activate nearby neurons, astrocytes, and other microglia.  Microglia are normally in 
a quiescent surveillance state and function to support, insulate, and protect neurons. Microglial 
cells also mediate innate immunity in the CNS,
122
 along with other mononuclear phagocytes. In 
addition, microglia and macrophages are thought to be on a continuum of activation anywhere 
between a classically activated proinflammatory state and an alternatively activated anti-
inflammatory state.
281
  
Astrocytes are derived from the neuroectoderm and make up more than 50% of the total 
glial population in the CNS. Astrocytes help to support neurons and develop and maintain the 
BBB
34
 and are also unique in that they can release neurotransmitters. Astrocytes can both 
synthesize D-serine for glutamate production and deactivate glutamatergic activity by taking up 
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extracellular glutamate.
32
 Astrocytes also encapsulate synapses and are in close contact with 
neurons, which allows them to directly alter neuronal communication.
126
 Astrocytes express 
multiple neurotransmitter receptors including N-methyl-D-aspartate receptors (NMDAR), 
metabotropic glutamate receptors, substance P receptors, and purinergic receptors.
250
  During 
chronic inflammation, microglia become activated first and astrocytes become activated later and 
can remain activated for long periods of time in response to the release of proinflammatory 
mediators from the microglia.
147
 
Glia become activated in response to neurotransmitters, calcitonin gene related peptide 
(CGRP), chemokines, cytokines, substance P, matrix metalloproteinases (MMPs), 
prostaglandins, nitric oxide, adenosine triphosphate (ATP), and their exposure to endogenous 
danger signals that are released by stressed, damaged, and dying/dead cells that are injured due 
to trauma, ischemia, cellular and metabolic stress, inflammation, or infection.
166
 Upon activation, 
glial cells undergo a set of functional and morphological changes.
59
 They retract their processes, 
increase soma size, display activation markers, and release a host of proinflammatory molecules 
that can lead to neuronal hyperexcitability, pain amplification, and chronic inflammation.
345
 
Markers of microglial activation include complement receptor 3 (CD11b/c), actin binding protein 
Iba1, the pattern recognition receptor toll-like receptor 4 (TLR4), and major histocompatability 
complex II, while the major marker of astrocyte activation is glial fibrillary acidic protein 
(GFAP).
326
 Of note, there are no markers that are exclusive to microglia. Interestingly, glia can 
also release anti-inflammatory molecules, which work to ameliorate neuropathic pain and restore 
normal pain signaling.
344
 Since glia can be both pathological and protective (see below for 
discussion), they are excellent therapeutic targets for neuropathic pain. However, central 
neuropathic pain is complex and the underlying mechanisms have still not been fully elucidated, 
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nor are there effective treatments available. The purpose of this dissertation is to help try and 
elucidate some of these mechanisms, specifically focused on glia, and provide novel therapeutic 
targets.  
The Role of Glia in Pain Processing 
 Glial cells are now recognized to play a very important role in pathological pain 
processing and have been implicated in many models of both peripheral and central neuropathic 
pain. Neuropathic pain is extremely difficult to treat, and there are currently no effective 
treatments available. Targeting glial cells for neuropathic pain management could provide 
chronic pain patients with better therapies and allow for a better quality of life. The following 
sections describe the role of glia in pain processing and how they might be targeted for central 
neuropathic pain control. 
Non-pathological pain processing 
Acute pain signaling occurs when a stimulus, such as stepping on a nail, activates 
peripheral nerve terminals on first-order primary afferent neurons called nociceptors. 
Nociceptors contain transient receptor potential (TRPA, TRPM, and TRPV) channels, sodium 
channels (Nav), potassium channels (KCNK), and /or acid-sensing ion channels (ASICs). These 
primary sensory neurons convey noxious (thermal, mechanical, chemical) signals through the 
cell body in the dorsal root ganglion (DRG) to secondary pain projection neurons in laminae I 
and V of the dorsal horn of the spinal cord through three major types of axon fibers: Aβ (large, 
myelinated, fast conducting, non-noxious signals), Aδ (smaller, myelinated, slower conducting, 
noxious signals), and C (smallest, unmyelinated, slowest conducting, noxious signals).
208
 The 
axon terminals of these fibers form the presynaptic element of the central synapses of the central 
sensory pathway in the spinal dorsal horn or trigeminal nuclei. Activation of these fibers by 
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noxious stimuli leads to glutamate, substance P, and/or CGRP release from these central 
presynaptic afferent nerve terminals in the spinal cord dorsal horn. The axons of second-order 
nociceptive pain projection neurons in the spinal cord dorsal horn decussate and join the 
ascending fibers of the anterolateral system where they project to and terminate in the rostral 
ventral medulla (RVM), the periaqueductal grey, or the thalamus, where they transfer 
information about the intensity and duration of the peripheral noxious stimulus. Third order 
neurons from thalamic nuclei including the ventral posterior, intralaminar, and parafascicular 
nuclei project to the primary and secondary somatosensory cortex, anterior cingulate cortex, 
amygdala, insular cortex, and pre-frontal cortex, which can encode different aspects of pain 
including sensory-discriminative, emotional, and cognitive aspects.
136
  
Pathological pain processing in neurons and glia 
Neuropathic pain arises when there is ongoing nerve injury and inflammation in the 
spinal cord even after the original damage has resolved. Much more is known about neuropathic 
pain arising from peripheral nerve injury compared to central neuropathic pain, therefore this 
section will describe neuropathic pain in terms of peripheral nerve injury, although there are 
some known differences between mechanisms underlying peripheral and central neuropathic 
pain that will be discussed. 
Neuropathy elicits changes in the activity and properties of neurons. Mechanoreceptors 
can become sensitized to applied mechanical stimuli,
268
 and damaged nerves can exhibit ongoing 
ectopic activity due to the accumulation of sodium channels around damaged axons. This 
aberrant activity can spread to the DRGs and nerve fibers can cross-excite each other, which is 
known as ephaptic transmission and can cause spontaneous pain and prime the spinal cord to 
amplify responses to subsequent stimuli.
55
 As discussed above, many of the primary sensory 
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neurons utilize the excitatory neurotransmitter glutamate. Binding of glutamate on post-synaptic 
spinal neurons leads to depolarization via α-amino-3-hydroxy 5-methyl-4-isoxazeloproprionic 
acid (AMPA) receptors,
246
 NMDA receptors,
221
 and the G-protein coupled metabotropic 
(mGluR) family of receptors.
359
 In addition, there are presynaptic kainate receptors for glutamate 
in the spinal cord.
157
 AMPA receptor activation normally sets the baseline responses of dorsal 
horn neurons, but if there is repetitive high frequency stimulation of AMPAR on these neurons, 
there is an amplification and prolongation of the response which is known as wind-up and results 
from activation of NMDARs.
67
 Acute or low frequency inputs to the spinal cord do not activate 
NMDARs because it is blocked by a magnesium ion (Mg
2+
) plug. Only sustained membrane 
depolarization is enough to remove the Mg
2+
 block and activate NMDARs, resulting in a large 
calcium ion (Ca
2+
) influx which can activate various effectors including nitric oxide synthase,
27
 
calcium/calmodulin-dependent kinases (CaMKI/II), and extracellular-related kinases (ERK), 
which can all lead to plasticity such as long-term potentiation (LTP).
196
  NMDAR activation 
plays a key role in inflammation and chronic pain, especially hyperalgesia (amplified responses 
to painful stimuli).
293
  
Descending pathways from the brainstem can also influence pain signaling in the dorsal 
horn. NK1 (neurokinin 1 receptor for substance P) positive neurons in the brainstem initiate 
descending facilitation through parabrachial-rostral ventral medulla connections down to 
serotenergic (5-HT3) receptors in the spinal cord, promoting neuropathic pain.
55
 Descending 
inhibition involves the release of norepinephrine from the brainstem (locus coeruleus) into the 
spinal cord where it acts at α2-adrenoceptors, inhibiting transmitter release from primary afferent 
terminals and suppressing firing of dorsal horn neurons.
204
 Another inhibitory pathway is 
through [gamma]-aminobutyric acid (GABA) interneurons in lamina II of the dorsal spinal cord. 
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Normally these GABAergic interneurons inhibit laminae I and V neurons, but following 
peripheral nerve injury, the ongoing activity from primary afferent neurons can cause a 
degeneration of these GABAergic interneurons. This results in decreased inhibition of the pain 
pathway and contributes to hypersensitivity, apoptosis, and chronic pain.
278
   
It is also possible to switch neurons that normally respond to noxious stimuli to now 
respond to non-noxious stimuli. Lamina I neurons do not receive direct input from low-threshold 
Aδ and Aβ afferents and they normally respond to noxious stimuli.189 However, in neuropathic 
pain situations, there is a disruption of chloride anion (Cl
-
) homeostasis that weakens inhibition 
of these lamina I neurons and causes them to be activated in response to normally non-noxious 
stimuli.
156
  
 Neurons in the spinal cord can become sensitized and amplify the normal pain response 
from any of a multitude of mechanisms including those reviewed above. This amplification of 
pain is referred to as central sensitization.
368
 Central sensitization results in increased responses 
to painful stimuli (hyperalgesia) and pain resulting from normally non-noxious stimuli 
(allodynia). Sensitized primary afferent neurons release an exaggerated amount of substance P, 
glutamate, CGRP, the chemokines fractalkine and monocyte chemoattractant protein 1 (MCP1), 
and ATP, which can now activate glia as well as feedback to activate other sensitized neurons. In 
addition, prolonged neuronal excitation can also activate mitogen-activated protein kinases 
(MAPKs) ERK, Jun N-terminal kinase (JNK), and p38 in glia, and each of these kinases can 
activate the transcription factor nuclear factor-κB (NFκB) which can synthesize a variety of 
different proinflammatory substances that can then go on to activate other neurons and 
surrounding glia, thereby amplifying pain and inflammation.
208
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Similarities and differences between peripheral and central neuropathic pain  
Central neuropathic pain is defined as “pain arising as a direct consequence of a lesion or 
disease affecting the somatosensory system”.320 Secondary pain that arises from a central 
process, such as shoulder-hand syndrome that arises after stroke or painful spasticity after MS, is 
not considered central pain. In addition, changes in the CNS secondary to a peripheral lesion are 
also not considered changes arising from central pain.
341
 In order to distinguish central 
neuropathic pain from peripheral neuropathic pain in SCI, a mechanism-oriented classification is 
used. Below-level pain is central pain as it is a direct consequence of spinal cord damage, 
whereas at-level pain is often due to peripheral nerve root injury and muscle spasms, which are 
not considered central pain.
288
 Although there is activation of ERK 1/2 , p38 MAPK, and 
CaMKII in both at- and below-level pain, activation of JNK is specific to below-level pain.
138
 
Activated microglia in SCI with below-level pain produce and regulate prostaglandin E2 via 
activation of pERK 1/2 MAPK, which maintains central neuropathic pain by inducing 
hyperexcitability in dorsal horn sensory neurons. This is mechanistically different than in 
peripheral neuropathic pain where microglial activation plays more of a role in the initiation 
rather than maintenance of pain and does not induce long-term hyperexcitability in neurons.
365
 In 
contrast to most peripheral neuropathies, central neuropathic pain can have a delayed onset.
5
 
Furthermore, studies have shown that lesions within the central nociceptive pathways are 
necessary for the development of both peripheral and central neuropathic pain,
341
 but are not 
sufficient to generate central neuropathic pain and must be accompanied by additional 
excitotoxic and inflammatory processes in order to initiate and maintain central neuropathic 
pain.
91
 Similar to peripheral neuropathic pain, both spontaneous and evoked pain can be present 
in central neuropathic pain.
235
 In addition, increased expression of voltage-gated Nav1.3 sodium 
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channels in the spinal cord triggered by inflammatory processes and glial activation can maintain 
both peripheral and central neuropathic pain.
117
 
Glia activation in central neuropathy 
It is well established that glia are activated by peripheral nerve injury,
191, 309
 but glia are 
also activated by direct CNS trauma. In both humans and in animal models of TBI, microglial 
activation persists for weeks to even years after the initial trauma, especially in moderate to 
severe cases.
150, 219, 227
 In animal models, chronic microglial activation increases expression of 
interleukin (IL)-1β and tumor necrosis factor (TNF)-α and is implicated in post-TBI 
neurodegeneration.
130, 190
 In humans, chronic microglial activation is associated with cognitive 
dysfunction
254
 and post-mortem studies demonstrate that reactive microglia in the corpus 
callosum and frontal lobe are up-regulated years after TBI.
298
 Glial activation has also been 
implicated in different models of MS including experimental autoimmune encephalomyelitis 
(EAE),
256
 and the cuprizone and lysolecithin demyelinating models.
212, 279
 Glial activation is 
associated with inflammation-induced neurodegeneration, and the putative glial activation 
inhibitor minocycline decreases demyelination and improved motor coordination.
241, 295
 Both 
microglia and astrocytes are activated in animal models of Parkinson’s322 and stroke,236, 267 and 
switching microglia from a classical proinflammatory state to an alternatively activated anti-
inflammatory state is associated with better functional outcomes following stroke.
148, 287
  
Glial activation and inflammation in spinal cord injury (SCI) 
Finally, SCI , which is the focus of this dissertation, is one of the main causes of 
disability worldwide,
261
 and more than 65% of SCI patients develop neuropathic pain.
289
 Glial 
activation is implicated in nearly every animal model of SCI including hemisection,
355
 
rhizotomy,
305
 contusion,
38
 and avulsion.
46
 Furthermore, attenuating glial activation improves 
10 
 
functional outcomes and decreases SCI-induced central neuropathic pain.
78, 111
 During SCI, there 
is a large amount of tissue trauma, glial activation, recruitment and infiltration of peripheral 
immune cells, and break down of the BBB, which can be compromised for up to twenty-eight 
days post-SCI.
248
 Neutrophils signal the first inflammatory response after SCI, they infiltrate the 
spinal cord within the first hour after injury and peak at twenty-four hours post-injury,
73
 but are 
gone by one week post-injury.
303
 Activated glia and macrophages are apparent fairly early 
following SCI and remain activated for about four weeks post-injury, but can be activated for 
much longer.
112, 249
 B and T lymphocytes infiltrate the injured spinal cord by six hours post-
injury and are usually gone by one week.
277
 It is also important to note central neuropathy and 
inflammation takes much longer to resolve than that of peripheral origin. The spinal cord trauma 
and inflammation that results after SCI induces a massive release of endogenous danger signals 
that can be sustained across years after the original tissue damage due to the extremely slow 
neurodegeneration and clearance of damaged tissue that occurs in the CNS.
329
 This enduring 
inflammation and glial cell activation induces a sustained release of proinflammatory mediators 
that can sensitize neurons and amplify pain and inflammation for months or even years. 
However, inflammation is not always pathological and the initial neuroinflammatory 
response is often adaptive and beneficial, and activated glia can actually be neuroprotective in 
certain cases. Macrophages and microglia promote regeneration of axons by scavenging myelin, 
and they can clear neuronal and other cellular debris produced by pathogens or apoptotic or 
necrotic cells during inflammation by phagocytosis.
199
 Activated glia often down-regulate 
proinflammatory cytokines to limit damage to nearby healthy tissue.
82, 201
 Without clearance of 
this toxic cell debris by activated glia, toxicity could easily spread throughout the CNS.
324
 
Activated glial cells can also produce the pro-regenerative cytokine, transforming growth factor-
11 
 
beta (TGF-β) and enhance neurite outgrowth.303 IL-10 is an anti-inflammatory cytokine that is 
released in response to neuroinflammation, and microglia activated in response to CNS damage 
can release IL-10 in order to decrease inflammation.
115
 Activated microglia can also help with 
wound healing in the CNS.
281
 Toll-like receptor 4 (TLR4) activation can also mediate microglial 
neuroprotection in certain situations.
208
  It has also been suggested that CD4+ T-cell mediated 
neuroprotection is dependent on microglial activation.
33
 Therefore, it is important to recognize 
that glial activation can be protective in certain cases, and it is only when pain and inflammation 
becomes severe and chronic (ie. pathological) that glial activation is pathological and should be 
attenuated.    
Targeting glia for treating central neuropathic pain 
There are three main ways of targeting glia for therapeutic benefit: attenuating glial 
activation using glial activation inhibitors, using compounds that inhibit cytokine production or 
action, and administering anti-inflammatory compounds. Although there are very few current 
compounds in clinical trials or use (see chapter V for a discussion of those that are), there are a 
number of promising pre-clinical treatments being used in research settings.  
One group of glial activation inhibitors is phosphodiesterase inhibitors (PDEs), which 
include propentofylline (PPF) and ibudilast. PDEs hydrolyze cAMP and/or cGMP, thereby 
inactivating these second messengers in the cyclic nucleotide signaling cascade.
51
 When PDEs 
are inhibited, the subsequent increase in cAMP decreases proinflammatory cytokines,
243
 reduces 
immune cell infiltration/activation and free radical formation,
11
 and increases production of the 
anti-inflammatory cytokine IL-10,
290
 resulting in less pain and less glial activation. Another set 
of glial activation inhibitors are macrophage migration inhibitory factor (MIF) inhibitors which 
include ibudilast. MIF is a ubiquitously distributed protein that is now considered to be a 
12 
 
cytokine
2
 and signals through ERK 1/2 and AKT.
181, 193, 210
 MIF increases firing in nociceptive 
neurons and induces proinflammatory gene transcription in microglia,
2
 and MIF inhibition is 
thought to decrease both of these. MIF is increased in compression SCI
165
 and intrathecal 
recombinant MIF elicits pain in naïve mice.
2
 Mice with SCI deficient in MIF do not develop 
neuropathic pain, have better functional recovery, and have fewer apoptotic neurons.
226
 In 
contrast, MIF can reduce secondary damage following SCI.
83
 A third type of glial activation 
inhibitors are drugs that block TLR4 activation, a glial receptor implicated in glial activation in 
response to a variety of endogenous danger signals. The (+)- isomers of naloxone and naltrexone 
attenuate glial activation in this manner.
26
 PPF, ibudilast, and (+)-naltrexone all attenuate SCI-
induced neuropathic pain,
78
 suggesting that these compounds may have some clinical utility. 
Minocycline, a second-generation tetracycline antibiotic also attenuates glial activation, likely by 
preventing cytokine and nitric oxide (NO) production and reducing microglial trafficking to 
injured neurons.
265
 Minocycline does decrease macrophage/microglial activation in SCI,
240
 but 
its clinical utility is limited because of the many side effects and difficulty of administration.  
Compounds that inhibit cytokine production include the IL-1β antagonist anakinra 
(Kineret) as well as the TNF-α antagonist etanercept (Enbrel). Both of these are known to 
provide better functional recovery after SCI in rodents,
133, 361
 but one limitation of these 
compounds is that they do not cross the BBB, which could limit their therapeutic potential for 
central neuropathic pain.  
Anti-inflammatory compounds include adenosine A2A receptor agonists such as 
CGS21680 and ATL313, which are thought to treat pain by attenuating glial activation by 
decreasing TNF-α and increasing IL-10 production via increases in cAMP mediated production 
of protein kinase A and C.
191, 192
 IL-10 gene therapy is also successful in treating neuropathic 
13 
 
pain,
297
 and, very recently, in dogs with arthritis (unpub obs.). Sustained release of IL-10 is 
thought to be able to cause a shift in both immune cells and the microenvironment from 
proinflammatory to anti-inflammatory, thereby relieving neuropathic pain for a prolonged period 
of time.
299
  
Although all of the compounds described above are thought to act primarily on glial cells, 
it is extremely important to note that none of them are truly specific to glial cells. Neurons have 
receptors for and express IL-1β and TNF-α,50, 233 they have adenosine A2ARs,
202
 TLR4,
70
 and can 
be modulated by PDE and MIF inhibition.
94
 Co-administering PPF and the competitive NMDAR 
antagonist (3-(2-carboxipiperazin-4)1-propyl phosphonic acid) (±)-CPP had additive effects, 
resulting in a blockade of the calcium current and intracellular transduction process in neurons, 
leading to decreased neuropathic pain.
215
 Ibudilast exerts neuroprotection on hippocampal 
neurons by inhibiting calcium influx and by sustaining a high level of cAMP.
319
 Naltrexone can 
decrease neuronal firing rate in prefrontal cortex
169
 and can decrease demyelination in EAE.
252
 
CGS21680 can increase sleep and the number of GABAergic neurons expressing Fos in the pre-
optic hypothalamus
172
 and can exert survival activity of motor neurons via activation of the 
adenylate cyclase-cAMP-PKA pathway and the TrkB neurotrophin receptor.
167
 However, upon a 
review of these literatures, it appears that, in large part, effects of the drugs under study in this 
dissertation have effects on neurons that largely arise secondarily from the effects of the drugs on 
glia. 
Although they have distinct functions, macrophages behave very similarly to microglia 
and can infiltrate from the periphery where they can differentiate into microglia in the CNS.
326
 
Macrophages and other immune cells express receptors for and release proinflammatory 
cytokines,
330
 IL-10,
50
 TLR4,
182, 286
 have adenosine A2ARs,
89
 and again like neurons can be 
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modulated by PDE and MIF inhibition.
94, 181
 PPF suppresses the production of TNF-α154 and 
reactive oxygen species in macrophages,
9
 and can also counteract neutrophil activation by 
blocking the removal of adenosine.
363
 Both PPF and ibudilast can prevent kainite-induced cell 
death in oligodendroglia,
358
 and ibudilast can also inhibit platelet aggregation in the presence of 
endothelial cells.
259
 Furthermore, ibudilast reduces inflammatory cell infiltration into the dorsal 
spinal cord in EAE. Naltrexone can suppress morphine-induced HIV replication in neonatal 
monocyte-derived macrophages.
185
 CGS21680 can reduce the number of infiltrated granulocytes 
into ischemic tissue
202
 and ATL313 can reduce inflammation in SCI via activation of A2AR on 
bone-marrow derived cells.
186
 Therefore, these compounds and all of those discussed in the 
chapters below could potentially be acting directly and/or indirectly on neurons and other 
immune cells as well as glia. However, there is a large body of literature that suggests that the 
primary actions of the compounds used in this dissertation are on glial cells.    
Glia and Adenosine Signaling 
Adenosine receptors are found on all cell types in the body, including glial cells. 
Adenosine agonists and antagonists have recently gained attention for the many therapeutic 
effects seen in neurodegenerative, autoimmune, and chronic pain disorders. Agonism of the 
adenosine A2AR induces an up-regulation of the anti-inflammatory cytokine IL-10, which is 
released by multiple cell types including glial cells. The following sections will describe the role 
of adenosine, IL-10, and glial cells in pain and inflammation.  
 Adenosine signaling 
 A large role of adenosine receptors is to regulate the inflammatory processes that occur 
after injury and trauma, and adenosine receptors have been a recent focus for neuropathic pain 
targets.
97
 Adenosine is a purine nucleoside that can signal through four different types of G-
15 
 
protein-coupled-receptors, adenosine receptors (ARs), A1, A2A, A2B, and A3.
369
 All four types are 
found on glial cells and can modulate the release of cytokines.
302
 AR signaling can occur through 
activation or inhibition of adenyly cyclase, phospholipase C, and MAPKs, and activation of A1 
and A3 decrease cAMP, while activation of A2A and A2B increase cAMP.
146
 The main source of 
extracellular adenosine is ATP, which is released from all cells at a basal level and is 
significantly increased in response to inflammation, tissue damage, and nerve injury.
71, 198
 Of 
note, the spinal cord trauma and inflammation that results after SCI induces a massive release of 
endogenous danger signals, including ATP, and ATP can signal through P2 purinergic receptors 
which can activate spinal glial cells and induce neuropathic pain.
222
 Other sources of 
extracellular adenosine include passive transport from intracellular pools and from intracellular 
cAMP or extracellular cAMP released from damaged cells.
275
 
  Extracellular adenosine levels are extremely variable depending on the tissue and degree 
of injury, and the effects of adenosine agonists and antagonists on central disorders are often 
confusing and opposing. The effects depend on the model, the timing, the tissue, the dose, and 
the specific cellular milieu surrounding the microenvironment. This is likely due to the ability of 
these receptors to adapt to and change within their local environment. For example, A2AR 
agonists are neuroprotective in acute brain damage following stroke, but are neurally detrimental 
in experiments looking at chronic effects of brain damage after stroke.
302
 In a mouse model of 
TBI, when Dai et al. administered the A2AR agonist CGS21680 at post-TBI times when brain 
glutamate levels were low, behavioral deficits and mRNA expression of TNF-α, IL-1β, and 
inducible nitric oxide (iNOS) were attenuated, but if CGS21680 was administered at post-TBI 
times when brain glutamate levels were high, behavioral deficits and cytokine expression were 
exaggerated beyond TBI plus vehicle.
56
 Furthermore, if CGS21680 was administered during 
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high glutamate levels post-TBI, pre-TBI treatment with a glutamate release inhibitor had 
neuroprotective effects, suggesting that glutamate levels can influence whether or not A2AR 
activation leads to a proinflammatory or an anti-inflammatory response. It has also been 
hypothesized that A2AR agonism on immunocompetent cells such as microglia and macrophages 
results in anti-nociception, while A2AR agonism of peripheral nerve cells is pro-nociceptive.
139
  
 Role of A2AR in SCI 
In animal models of SCI, A2AR agonists have multiple therapeutic effects. In mouse 
models of SCI, the selective A2AR agonist ATL313 reduced motor deficits and demyelination,
186
 
and both ATL313 and CGS21680 decreased TNF-α expression in the spinal cord.101 A different 
A2AR agonist, ATL146e, decreased paralysis in rabbits with contusion SCI twelve hours post-
surgery compared to controls.
40
 Although there are multiple studies that examine anti-allodynic 
effects of A2AR agonism in peripheral neuropathic pain,
28, 183, 191
 the studies discussed in chapter 
III are the first to examine the anti-allodynic effects of A2AR agonism in central neuropathic 
pain. One of the possible mechanisms for the anti-inflammatory and anti-allodynic effects of 
A2AR agonism in SCI is a down-regulation of proinflammatory cytokines and an up-regulation of 
the anti-inflammatory cytokine IL-10. 
 IL-10 and alternative activation 
 IL-10 is a potent anti-inflammatory cytokine that is produced by glia and immune cells as 
well as neurons. IL-10 is released in response to inflammation in order to help control the 
proinflammatory response through negative feedback and also to help with wound healing.
163
 
The IL-10 receptor is a heterotetramer compromised of four chains, two IL-10R1 and two IL-
10R2 where IL-10R1 is critical for IL-10 binding and signal transduction and has a high affinity 
for the IL-10R complex, and IL-10R2 is only required for signaling and can be part of the 
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receptor complexes of other cytokines.
168, 360
 When IL-10 binds IL-10R1, IL-10R1 then interacts 
with IL-10R2 to activate Jak1 and tyrosine kinase 2 of the Janus kinase family.
217
 These 
phosphorylate IL-10R1 which allows phosphorylation and binding of signal transducer and 
activator of transcription 3 (STAT3), which ultimately leads to anti-inflammatory activity. IL-10 
can inhibit NFκB and MAPK signaling, thereby suppressing proinflammatory cytokine 
production.
48, 206
   
There is both clinical and pre-clinical evidence that IL-10 is therapeutic in SCI. Human 
neuropathic pain patients have decreased levels of IL-10 in cerebrospinal fluid (CSF) compared 
to healthy controls, and these decreased levels correlate to higher pain scores.
8
 Acute systemic 
administration of IL-10 in a rat contusion model of SCI reduced expression of TNF-α in spinal 
cord and increased motor recovery and decreased lesion size two months post-injury.
20
 However, 
there are also instances where IL-10 in SCI can be deleterious. Interestingly, chronic systemic 
administration of IL-10 is detrimental to recovery in SCI and can even increase peripheral 
neuropathy.
317
  Also, if IL-10 is administered intrathecally immediately after SCI, indices of 
injury are exacerbated.
25
 It is thought that a single immediate intrathecal injection or chronic 
systemic injections are detrimental because they do not allow recruitment of monocytes to the 
injury site where they would be able to release local IL-10 and participate in phagocytosis and 
wound healing.
285
  
It is now accepted that macrophages can exist in a spectrum of different states of 
activation. The definition of the different activation states of these cells was originally based on 
in vitro studies of peripheral monocytes/macrophages, which was later confirmed in vivo in 
rodents.
107
  Classical activation of macrophages, also known as the M1 phenotype, is caused by 
the soluble cytokine interferon (IFN)-γ and results in the expression of high levels of 
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proinflammatory cytokines and increased microbicidal capacity.
57
 Alternative activation of 
macrophages, also known as the M2 phenotype, is split into two different categories based on 
function. This first is wound healing, which is stimulated by the release of IL-4 and IL-13 from T 
helper 2 (Th2) lymphocytes and results in the up-regulation of mannose receptor and arginase-
1.
22
 The other category is regulatory/anti-inflammatory, and is stimulated by the release of IL-10 
from microglia and macrophages, resulting in further increases in IL-10.
217
 It is thought that the 
same macrophage can adopt either a more proinflammatory M1-like or more anti-inflammatory 
M2-like phenotype depending on the stimulus, and can switch back and forth between the 
phenotypes as the microenvironment changes.
216
 The question remains whether microglia can 
also adopt these different activation states/phenotypes. Part of the difficulty in assessing 
microglial activation states is the lack of a specific marker for simply identifying microglia, as 
macrophages also express the same markers, and the mechanisms of how these phenotypes are 
regulated in microglia are still poorly understood.
22
 However, it is clear that microglia do express 
differential phenotypes depending on the stimulus and environment. 
Microglia can respond differently to the same stimulus depending on what, if any, signals 
precede or follow the initial stimulus. For example, microglia can be “primed”, where the first 
stimulus primes the cell to have an exaggerated response upon activation by a second stimulus.
96
 
Microglia can also become activated by small amounts of T-cell-derived TNF-α without 
releasing TNF-α themselves.281, 284 Small doses of TNF-α or IFN-γ can make microglia exert 
neuroprotective effects, whereas larger doses then cause a switch in the microglia to now become 
cytotoxic.
19, 31
 When microglia are exposed to a proinflammatory environment and then 
subsequently encounter the anti-inflammatory Th2 cell-derived cytokine IL-4, the microglia can 
switch to a more anti-inflammatory/protective phenotype.
30
 Finally, there is a group of microglial 
19 
 
cells that are thought to be quiescent up to a certain age, but become increasingly dysfunctional 
with the aging process.
281
     
Glia and the Immune System 
The way that the body responds to invading pathogens is by activating the innate immune 
response. The very first line of defense is the physical barrier made up of the epithelium (skin, 
gut, lungs), but there are many other components that make up the innate immune system. These 
include pattern recognition receptors (PRRs) such as toll-like receptors (TLRs), nucleotide-
binding and oligomerization domain leucine-rich repeats containing (NOD)-like receptors 
(NLRs), scavenger receptors (SRs), and glial cells. The following sections will discuss the role 
of glia in innate immunity. 
 Glia as immune cells 
 Microglial cells are of myeloid origin
103
 and both microglia and astrocytes, like other 
classical innate immune cells (macrophages, dendritic cells), become activated by recognizing 
specific molecular patterns on pathogens.
225
 These molecular patterns are termed pathogen-
associated molecular patterns (PAMPs) and are recognized by PRRs on glia cells. In addition to 
recognizing pathogens, it is now known that the innate immune system also responds to 
endogenous “danger” signals that are released by damaged/dying cells such as that seen in SCI 
and other traumatic and inflammatory diseases.
43
 These danger signals are termed  danger 
associated molecular patterns (DAMPs) and include things like ATP, heat shock proteins, and 
high mobility group box 1 (HMGB1), although there are many others that have been 
identified.
234
 These DAMPs bind to and activate TLRs, which induce different immune-like 
intracellular signaling cascades.
208
 There are currently 13 different TLRs, and TLR2 and TLR4 
are important in neuropathic pain and are expressed predominately on microglia (although can 
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also be expressed on astrocytes and neurons).
39, 336
 Furthermore, DAMPs activate glia by binding 
to TLR4 which results in the release of the proinflammatory cytokines IL-1β, TNF-α, and IL-6.26      
 TLR4 signaling  
 Glial activation via TLR4 is heavily implicated in both peripheral and central neuropathic 
pain.
26, 144
 Although the exact details of how different DAMPs activate TLR4 is not entirely 
known, it is likely similar to activation of TLR4 by gram-negative bacteria such as 
lipopolysaccharide (LPS).The TLR4 signaling cascade will be described using LPS as the 
example ligand. TLR4 is a membrane bound receptor and LPS binding leads to intracellular 
activation of the enzyme acid sphingomyelinase which then generates ceramide (a bioactive 
lipid). Ceramide induces the generation of a lipid raft containing the co-receptor myeloid 
differentiation factor 2 (MD2) and TLR4 (there are other elements of the lipid raft that will not 
be discussed here). Ceramide also activates NADPH oxidase, leading to peroxynitrite formation, 
which is important in the development of many pain disorders including pain after chronic opioid 
use.
273
 CD14 then transfers the ligand to MD2, leading to both MD2-TLR4 heterodimerization 
and then homodimerization of the MD2-TLR4 pairs. Ensuing intracellular signaling occurs 
through toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) to at least three 
parallel pathways: the IP3K/Akt pathway (cell motility/survival/apoptosis/generation of NO and 
TNF-α), the NFκB pathways (proinflammatory cytokine transcription), and MAPK pathways.345 
In order to activate a proinflammatory response, the adaptor proteins myeloid differentiation 
primary response 88 (MyD88) and the TIR-domain-containing adapter-inducing interferon-β 
(TRIF) must bind to the intracellular domain of TLR4. Together these proteins activate the 
transcription factors NFκB, AP-1, and IRF-3, which leads to the expression of proinflammatory 
cytokines, including IL-1β and TNF-α.245 Also of importance for neuropathic pain, TLR4 is 
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activated by every clinically relevant class of opioids.
141, 142, 340, 345
 This is important because 
many neuropathic pain patients, and virtually all SCI pain patients, are treated with opioids at 
some point and there is evidence that opioids can have deleterious effects on health and recovery 
following injury.
132, 270
  
Although TLR4 is found predominately on glial cells in the spinal cord, it is also 
expressed on neurons in the brain and on peripheral cells.
182, 367
  Peripheral blood mononuclear 
cells (PBMCs) that were isolated from chronic pain patients and stimulated ex vivo with LPS 
released increased IL-1β compared to healthy controls,173 and trigeminal sensory neurons and 
hippocampal neurons express TLR4 and CD14 and can respond to LPS.
336, 364
 Diogenes et al. 
show that, in vitro, TLR4 co-localizes with capsaicin-sensitive TRPV1 in trigeminal sensory 
neurons and LPS increases capsaicin-induced CGRP release via TRPV1 and TLR4, causing a 
sensitization of these trigeminal neurons.
70
 Zhao et al. showed that cultured hippocampal neurons 
stimulated with LPS lead to increased expression of TNF-α and IL-1β via NFκB activation.364 
TLR4 may also be able to activate the PKC-ε signaling pathway, and PKC-ε leads to activation 
of sensory neurons via its expression in nociceptors.
228
 TLR4 is also found on non-nociceptive, 
non-myelinated, neurofilament H (NF-H) expressing neurons,
336
 and spinal nerve ligation can 
induce small diameter neurons to express NF-H.
120
 TLR4, MyD88, and TRIF are also up-
regulated in DRG neurons seven days after paclitaxel-related chemotherapy-induced peripheral 
neuropathy (CIPN), at which time rats were also allodynic. However, the up-regulation in TLR4, 
MyD88, and TRIF was gone by day fourteen even though rats were still allodynic at day twenty 
one, suggesting that TLR4 expression in DRG neurons is only contributing to acute, not chronic, 
neuropathic pain.
187
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Cytokine processing and inflammasomes 
TNF-α is important for initiating the proinflammatory response and neuropathic pain,6, 304 
especially in mediating thermal hyperalgesia.
300
 TNF-α has two receptors, the constitutively 
expressed TNFR1-p55R and the inducible (under inflammatory conditions) TNFR2-p75R, and 
binding to one or the other induces a differential response.
50
 Binding to the p55 subunit induces 
programmed cell death, but binding to the p75 subunit induces translocation of NFκB into the 
nucleus and stimulates the production of IL-1β.326 TNF-α and IL-1β released by activated glia 
can then produce and amplify pain by activating other surrounding glial cells, by acting directly 
on their receptors on neurons or by phosphorylating NMDA receptors on neurons, thereby 
increasing neuronal excitability by releasing other substances like D-serine that enhance NMDA 
channel function, and by activating p38 and ERK MAPK cascades.
208
     
IL-1β is also importantly involved in neuropathic pain and it is considered the 
“gatekeeper of inflammation”, and is therefore very tightly regulated.177 The way in which IL-1β 
is processed is different than most other cytokines; it must be cleaved from a precursor protein 
(pro-IL-1β) into a mature protein that can then be released. 327 The molecule that cleaves the pro-
form of IL-1β into the mature form is the protease caspase-1, although caspase-1 must also be 
cleaved from a precursor protein, pro-caspase-1.
174
 The way that pro-caspase-1 is cleaved is 
through the formation and activation of a group of intracellular proteins collectively called the 
inflammasome.
213
 The inflammasome complex is made up of a sensor molecule, the adaptor 
protein apoptotic speck protein (ASC), and the effector protein pro-caspase-1.
177
 The majority of 
the inflammasomes also contain a nucleotide-binding oligomerization receptor (Nod-like 
receptor, NLR), which acts as the intracellular sensor of alarmins.
66
 There are six NLR 
inflammasomes (NLRP1, 2, 3, 6, 7, and NLRC4), and three of these (NLRP1, 2, 3) have been 
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identified in the CNS.
121, 200, 209
 NLRP1 is found mainly on neurons, including motor neurons in 
the spinal cord,
63
 and NLRP2 is found mainly on astrocytes.
209
 However, NLRP3 is thought to be 
expressed only in myeloid cells and is the only one known to be expressed on microglia.
121
  
It is thought that the NLRP1 inflammasome in the CNS, unlike in the periphery, is 
preassembled, allowing for rapid activation of the innate immune response following trauma.
63
 
The NLRP1 inflammasome in the brain and spinal cord is a multi-protein complex made up of 
NLRP1, caspase-1, ASC, caspase-11, and the inhibitor of apoptosis proteinX-linked inhibitor of 
apoptosis protein (XIAP).
63
 SCI-induced activation of the NLRP1 inflammasome is associated 
with cleavage of XIAP, which is thought to reduce the threshold for activation of caspase-1, 
leading to amplified expression of IL-1β.62 Of note, XIAP is not associated with NLRP1 on 
peripheral immune cells.
170
 Pannexin-1 is thought to link P2X7 and P2X4 to the NLRP1 
inflammasome only in neurons, and deletion of P2X4 in mice following SCI significantly 
decreases NLRP1 inflammasome activation, production of IL-1β, and infiltration of immune 
cells into the injury site.
61
 NLRP2 consists only of NLRP2, ASC, and caspase-1 and normally 
inhibits NFκB.188 However, if NLRP2 in astrocytes is activated by a DAMP such as ATP, it 
interacts with P2X7 and pannexin-1 to initiate rapid cleavage of caspase-1 and production of 
mature IL-1β.62  
The NLRP3 inflammasome is the most studied and is unique in that basal NLRP3 protein 
expression is too low for actual formation/activation of the inflammasome.
14
 In order for NLRP3 
inflammasome formation to occur, the NLRP3 gene must first be transcribed and translated into 
protein. This step is thought to require TLR2 or 4 ligation, and is referred to as the “priming” 
step. After enough NLRP3 protein has accumulated, a second signal is required for NLRP3 to 
interact with ASC. NLRP3 is unusual in that it responds to a wide variety of second signals, 
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which include ATP, reactive oxygen species, and other alarmins.
135
 ASC can then recruit pro-
caspase-1, which results in the cleavage/activation of pro-caspase-1 which then cleaves pro-IL-
1β into its mature protein form. Although inflammasome-dependent processing of IL-1β is most 
common, there are also inflammasome-independent mechanisms for processing IL-1β. 
Although caspase-11 can directly process pro-IL-1β into mature IL-1β in the absence of 
caspase-1, it is very slow and inefficient.
339
 It is more likely that Caspase-11 is enhancing 
caspase-1 activation independently of inflammasome activation. Caspase-11 also directly 
controls the activation of the effector caspases 3 and 7 of the pyroptosis apoptotic pathway 
independent of caspase-1.
332
 Caspase-8 can also process pro-IL-1β into its mature form 
independent of inflammasome activation by activating a MALT1–caspase-8–ASC complex.110 
IL-1β release in human PBMCs induced by autophagy is also inflammasome-independent and is 
thought to involve the inhibition of p38 MAPK phosphorylation.
53
 Stimulation of microglia with 
ATP in acidic conditions induces the release of the 20-kDa form of IL-1β rather than the more 
commonly reported 17-kDa form,
76
 and the cleavage of the 20-kDa form does not require 
caspase-1 but instead depends on the protease cathepsin D.
310
 Both a cathepsin B inhibitor and 
caspase-1 inhibitor administered to cultured neonatal microglia from NLRP3 knock out (KO) 
mice that were stimulated with Staphylococcus aureus (S. aureus) bacteria attenuated IL-1β 
release, providing further evidence of inflammasome-independent processing of mature IL-1β.121 
Lastly, there are other non-caspase proteases that can cleave IL-1β into its mature form,88 
including proteinase-3, which is implicated in acute arthritis.
153
 
 
Theoretical Considerations and Thesis Overview 
There are more than a quarter million Americans suffering from chronic pain, a problem 
that costs millions of dollars and for which there are no truly effective treatments.
36
 Many of 
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these treatments target neurons, but it is important to consider other cell types that could be 
contributing to pain, including macrophages, other peripheral immune cells, and glial cells.  
Glial activation has been implicated in many different central pain disorders, however, 
this dissertation will focus on SCI, as it is one of the most prevalent and debilitating disorders. 
Furthermore, we have developed a novel rat model of unilateral T13/L1 avulsion SCI 
specifically to study the mechanisms, both glial and otherwise, that underlie central neuropathic 
pain.
261, 349
 Avulsion literally means “to rip out”, and dorsal root avulsions often happen in 
vehicle accidents, especially motorcycle accidents. Our avulsion model, termed Spinal 
Neuropathic Avulsion Pain (SNAP), causes actual spinal cord dorsal horn damage, and results in 
robust bilateral below-level central neuropathic pain that lasts for about two months.
349
 Our 
model is also unique in that it does not cause paralysis, autotomy, or urinary tract infections, 
which can confound the study of pain behavior. In addition, we know that blocking glial 
activation and the subsequent release of proinflammatory cytokines attenuates SNAP.
349
 
Interestingly, SNAP does not induce thermal hyperalgesia. However, thermal hyperalgesia is 
rarely seen in central neuropathic pain disorders because it usually indicates sensitization of 
peripheral afferents.
341
 It is well accepted in the pain literature that dorsal spinal cord glial 
activation and the consequent release of neuroexcitatory and neuroinflammatory mediators are 
necessary and sufficient for the induction and maintenance of chronic pain.
343
 This is perhaps 
why neuronally targeted treatments are ineffective; the glia are still activated and are able to 
maintain the pain state.  We hypothesize that glia, and their release of inflammatory mediators, 
amplify chronic SCI pain. Therefore, studying the behavioral and molecular changes associated 
with SCI pain and using the results to develop treatments that target glia could potentially yield 
much better results in SCI pain patients. The studies presented in chapter II discuss the effects of 
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administering three different glial activation inhibitors, PPF, ibudilast, and (+)-naltrexone in 
SNAP. Each of these compounds has a distinct mechanism of action but have each been 
documented to exert their primary effects on glial cells.  
Adenosine is found on every cell type throughout the body and is best known for its 
interaction with caffeine, which is a non-specific adenosine antagonist.
261
 There are four 
different types of adenosine receptors, and there is an expanding body of literature that shows the 
ability of adenosine A2AR agonists to decrease inflammation by suppressing proinflammatory 
and increasing anti-inflammatory cytokines in peripheral,
125
 and central,
191
 immune cells. 
Because of this, there has been a recent interest in developing A2AR agonists, such as CGS21680 
and ATL313, for clinical use. The studies in chapter III discuss the effects of giving a single 
acute intrathecal injection of an adenosine A2AR agonist in SNAP.  
The most effective and widely used therapy for central neuropathic pain is opioid 
treatment. However, recent studies in both clinical and preclinical models have shown that 
opioid treatment is actually detrimental to recovery.
131, 328
 Opioids amplify the magnitude and 
duration of chronic pain and suppress motor recovery,
132
 and opioid treatment can also cause 
constipation,
223
 which is a major problem in SCI. These deleterious effects of opioid 
administration impact almost every single SCI patient since they are universally treated with 
opioids, whether en route to the hospital, in the hospital during the acute phase of trauma, or long 
after the initial injury when chronic pain develops. Opioids activate TLR4 on glial cells,
145
 which 
in the presence of other endogenous danger signals that are massively released by damaged cells 
in the spinal cord during SCI; can actually amplify pain and neuroinflammation. The studies 
presented in chapter IV discuss the deleterious effects of administering a week-long course of 
systemic morphine shortly after SNAP.  
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Taken all together, the complete set of experiments described in this dissertation strongly 
suggest that spinal glia are significant contributors to the mechanisms underlying central 
neuropathic pain and neuroinflammation and are a promising therapeutic target for pain control. 
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Chapter II 
Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each Reverses 
Mechanical Allodynia in a Novel Rat Model of Central Neuropathic Pain 
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Scott 
Falci, and Linda R. Watkins 
 
Abstract 
Central neuropathic pain (CNP) is a debilitating consequence of central nervous system 
(CNS) damage for which current treatments are ineffective. To explore mechanisms underlying 
CNP, we developed a rat model involving T13/L1 dorsal root avulsion. The resultant dorsal horn 
damage creates bilateral below-level (L4-6) mechanical allodynia. This allodynia, termed spinal 
neuropathic avulsion pain (SNAP), occurs in the absence of confounding paralysis. To 
characterize this model, we undertook a series of studies aimed at defining whether SNAP could 
be reversed by any of 3 putative glial activation inhibitors, each with distinct mechanisms of 
action. Indeed, the phosphodiesterase inhibitor propentofylline, the macrophage migration 
inhibitory factor (MIF) inhibitor ibudilast, and the toll-like receptor 4 (TLR4) antagonist (+)-
naltrexone each reversed below-level allodynia bilaterally. Strikingly, none of these impacted 
SNAP upon first administration but required 1-2 weeks of daily administration before pain 
reversal was obtained. Given reversal of CNP by each of these glial modulatory agents, these 
results suggest that glia contribute to the maintenance of such pain and enduring release of MIF 
and endogenous agonists of TLR4 is important for sustaining CNP. The markedly delayed 
efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug 
failures after shorter dosing regimens.  
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Introduction 
 
Central neuropathic pain (CNP) is a common and debilitating consequence of a variety of 
different central nervous system (CNS) traumas including spinal cord injury (SCI), stroke, 
traumatic brain injury (TBI), and multiple sclerosis (MS). The percentage of patients that 
develop central pain following trauma range from 8% in stroke, 25% in MS, 50% in TBI, and up 
to 66% in SCI.
23, 224, 289
 Mechanisms underlying CNP are poorly understood, and current 
pharmacotherapies for treating this type of pain are not effective.  
CNP is extremely difficult to treat, and current therapies have limited response rates, 
provide only minor pain relief, and often have intolerable side effects. Classes of drugs 
commonly used to treat CNP include tricyclic antidepressants (TCAs), calcium channel 
trafficking inhibitors, anticonvulsants, and opioids.
90
 Using SCI as an example, a clinical SCI 
study found that gabapentin, which inhibits calcium channel trafficking,
128, 171
 was no more 
effective than the active placebo and that the TCA amitriptyline was slightly more effective than 
active placebo but resulted in undesirable side effects (nausea, bladder problems, 
constipation).
260
 Another clinical study found that the anticonvulsant drug lamotrigine did not 
relieve central pain in patients with MS.
24
 Although opioids are one of the most widely used and 
effective central pain treatments,
352
 the side effects and addiction problems that can arise from 
chronic use cause many pain patients to discontinue treatment.
17
 In addition, recent literature has 
shown that morphine given shortly after SCI can have deleterious effects on recovery.
131
 One 
commonality between all of these drugs is that their mechanisms of action are thought to be 
largely neuronal, but it is well known that glial cells that become activated after a traumatic 
inflammatory event play a large role in the induction and maintenance of a variety of chronic 
pain states of peripheral origin.
35, 109
 Examining the potential role of glia in mechanisms 
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underlying CNP may potentially lead to the development of more efficacious CNP treatments as 
well as improve our understanding of the mechanisms that underlie this type of pain. 
Since the complexities of CNS traumas make them extremely difficult to treat, it is 
important to consider not only neuronal targeting compounds, but also those treatments that 
target other cell types such as glia and macrophages. The current series of studies examined the 
effects of administering three different putative glial activation inhibitors, propentofylline (PPF; 
a phosphodiesterase (PDE) inhibitor),
220, 308
 ibudilast (some PDE actions but considered 
predominantly as a MIF inhibitor),
49
 and (+)-naltrexone (a non-opioid TLR4 antagonist),
144
 in a 
novel model of unilateral T13/L1 dorsal root avulsion SCI. Dorsal root avulsions are common 
after automobile and motorcycle accidents
18, 37
 and can cause below-level pain.
75, 85
 Our avulsion 
model creates a discrete dorsal horn spinal cord lesion resulting in bilateral below-level 
neuropathic pain (termed spinal neuropathic avulsion pain [SNAP]), but does not cause paralysis, 
gross white matter damage, or urinary tract infections that are inherent, at least in part, in most 
models of stroke, TBI, MS, and contusion and hemisection SCI.
349
 We developed this avulsion 
model in order to study pain behavior in isolation from such complicating factors so that we may 
better understand the specific mechanisms underlying CNP.  
Materials and Methods 
 
Animals 
All procedures were approved by the Institutional Animal Care and Use Committee of 
the University of Colorado at Boulder. The care and use of the animals also conformed to 
guidelines of the International Association for the Study of Pain. Pathogen-free male Sprague-
Dawley rats (325-350g; Harlan Laboratories, Madison, WI, USA) were used for all experiments. 
Rats were pair-housed prior to surgery and then single-housed after surgery with standard rat 
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chow and water available ad libitum. Housing was in a temperature-controlled room that was 
maintained at 23+/-2°C with a 12hr light/dark cycle (lights on at 0700 hr). The rats were allowed 
a minimum of 1 week to habituate to the colony room before initiating the experiment. All 
procedures were done during the light cycle.  
Drugs 
Propentofylline (PPF; a gift from MediciNova, San Diego, CA, USA and Solace/Patheon 
UK Ltd, Wiltshire, England) was dissolved in sterile endotoxin-free isotonic saline (Abbott 
Laboratories, Abbott Park, IL, USA) and administered at dose of 10 mg/kg per intraperitoneal 
(i.p.) injection. Controls received i.p. equivolume (1 ml/kg) saline. Ibudilast (MN-166; a gift 
from MediciNova, San Diego, CA, USA) was dissolved in 100% corn oil (Mazola) and 
administered at 10 mg/kg per subcutaneous (s.c.) injection. Controls received s.c. equivolume 
(0.5 ml/kg) corn oil. (+)-Naltrexone (a gift from NIDA and NIAAA, Rockville, MD, USA) was 
dissolved in sterile endotoxin-free isotonic saline (Abbott Laboratories, Abbott Park, IL, USA) 
and administered at 6 mg/kg per s.c. injection. Controls received equivolume (1 ml/kg) saline. 
All drugs were given systemically as they are all known to cross the blood brain barrier.
95, 144, 178
 
Spinal Neuropathic Avulsion Pain (SNAP) Surgery 
Unilateral (left) T13/L1 dorsal root avulsion was performed under isoflurane anesthesia, 
as previously described in detail.
348
 Briefly, laminectomy was performed at the T12 vertebral 
level and the dura mater was incised over the dorsal root entry zone. The T13 and L1 dorsal 
rootlets were carefully isolated and then clamped at the dorsal root entry zone and briskly pulled 
out (avulsed). Sterile saline-moistened surgical sponge was placed over the exposed spinal cord 
to protect it, the muscle was sutured in layers with sterile 3-0 silk, and the skin was closed with 
stainless steel wound clips. Immediately following surgery, rats were single-housed in a cage 
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with foam padding for a few hours to protect their spinal cord from further trauma due to the 
brief ataxic period that follows recovery from anesthesia. Sham operated rats were treated 
identically, except for avulsing of the rootlets. Combi-Pen-48 antibiotic (0.2 ml; Bimeda, Inc., Le 
Sueur, MN, USA) was administered at the time of surgery and daily for 4 days after surgery. 
Low Threshold Mechanical Allodynia Testing 
 
Prior to surgery, rats were habituated to the testing environment for 4 consecutive days 
prior to recording of behavioral responses. All von Frey assessments were performed blind with 
respect to drug and surgery assignments.  Assessment of von Frey thresholds occurred before 
surgery (baseline) and across a timecourse beginning two weeks after surgery. The von Frey test 
was performed on the plantar surface of each hind paw as previously described in detail.
205
 A 
logarithmic series of 10 calibrated Semmes–Weinstein monofilaments (Stoelting) were 
sequentially applied to the left and right hind paws in random order, each for 8 s at constant 
pressure to determine the stimulus intensity threshold stiffness required to elicit a paw 
withdrawal response. Log stiffness of the hairs is determined by log10 (milligrams x10). The 
range of monofilaments used in these experiments (0.407–15.136 g) produces a logarithmically 
graded slope when interpolating a 50% response threshold of stimulus intensity (expressed as 
log10 (milligrams x10)).
41
 The stimulus intensity threshold to elicit a paw withdrawal response 
was used to calculate the 50% paw withdrawal threshold (absolute threshold) using the 
maximum-likelihood fit method to fit a Gaussian integral psychometric function.
124
 This method 
normalizes the withdrawal threshold for parametric analyses.
124
 The general von Frey testing 
rubric is as follows. Rats are baselined before surgery and are allowed a 14 day recovery period. 
Rats are tested on a weekly basis on days 14, 21, and 28 post-surgery. Drug administration 
begins after the day 28 behavioral test, with one exception ((+)-naltrexone) where drug 
33 
 
administration began on day 32 post-surgery due to extenuating circumstances. Behavioral 
testing then occurs once per week until the conclusion of the study, except for when a more 
detailed timecourse was necessary to define when reversal of enhanced mechanical reactivity 
(allodynia) began to occur. In these studies, behavioral testing occurs every 2-3 days after drug 
administration.  
Pharmacological Manipulations 
Propentofylline (PPF) Timecourses 
 Daily PPF dosing began after development of SNAP was confirmed by von Frey testing 
14, 21, and 28 days after surgery. PPF (10 mg/kg) or equivolume vehicle (saline) was 
administered once daily for either 14 days or 35 days. PPF was administered between 1600-1800 
hr, and behavioral testing occurred approximately 15 hr later (0700-0900 hr), so to parallel 
previous publications.
314
 This delayed testing timepoint is standard when looking at glial effects 
of PPF in order to allow time for second messenger signaling cascades to exert their effects.
114, 
215, 251, 309, 315
 Rats were behaviorally tested to define their mechanical response thresholds every 
2-7 days until the final behavioral test 15 hr after the last dose of PPF or vehicle. 
Ibudilast Timecourse Later in the Development of SNAP 
Daily ibudilast dosing began after development of SNAP was confirmed by von Frey 
testing 14, 21, and 28 days after surgery. Ibudilast (10 mg/kg) or equivolume vehicle (corn oil) 
was administered once daily for 35 days. Ibudilast was administered between 0800-1000 hr each 
morning and testing occurred 1-2 hr later, so to parallel previous publications.
179
 Rats were 
behaviorally tested to define their mechanical response thresholds every 7 days until the final 
behavioral test 1-2 hr after the last dose of ibudilast or vehicle. 
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Ibudilast Timecourse Early in the Development of SNAP 
 Daily ibudilast dosing began after development of SNAP was confirmed by von Frey 
testing 14 days post-surgery. Ibudilast (10 mg/kg) or equivolume vehicle (corn oil) was 
administered once daily for 21 days. Ibudilast was administered between 0800-1000 hr each 
morning and testing occurred 1-2 hr later, as described above. Rats were behaviorally tested to 
define their mechanical response thresholds every 7 days until the final behavioral test after the 
last dose of ibudilast or vehicle. 
(+)-Naltrexone Timecourse 
 Daily (+)-naltrexone dosing began after development of SNAP was confirmed by von 
Frey testing 14, 21, 28, and 32 days after surgery. Given its relatively short half-life compared to 
ibudilast and PPF, (+)-naltrexone (6 mg/kg) or equivolume vehicle (saline) was administered 
three times a day for 14 days. (+)-Naltrexone was administered at approximately 0900, 1200, and 
1500 hr and testing occurred 1 hr after the second injection, based on our previous studies.
144
  
Rats were behaviorally tested to define their mechanical response thresholds every 7 days until 
the final behavioral test after the last dose of (+)-naltrexone or vehicle. 
(+)-Naltrexone Drug Cessation Timecourse 
 Daily (+)-naltrexone dosing began after development of SNAP was confirmed by von 
Frey testing 14, 21, and 28, days after surgery. Given its relatively short half-life compared to 
ibudilast and PPF, (+)-naltrexone (6 mg/kg) or equivolume vehicle (saline) was administered 
three times a day for 6 days. (+)-Naltrexone was administered at approximately 0900, 1200, and 
1500 hr and testing occurred 1 hr after the second injection, based on our previous studies. Rats 
were behaviorally tested to define their mechanical response thresholds daily until the final 
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behavioral test after the last dose of (+)-naltrexone or vehicle on day 33. Rats were then 
behaviorally tested every 2-6 days, at approximately 1300hr, until they returned back to pre-drug 
allodynia levels. Since we already observed that (+)-naltrexone had no effect on sham operated 
rats in the previous (+)-naltrexone study, and to conserve drug, sham groups were not included in 
this study. 
Statistical Analysis 
All data were expressed as mean ± standard error of the mean (SEM). Ipsilateral and 
contralateral behavioral data were analyzed individually. Behavioral measures were normalized 
as described above and group differences were analyzed by comparing area under the curve 
(AUC), as previously described by Jones and Sorkin.
152
 AUC values (GraphPad Prism 5.01; 
GraphPad software Inc., San Diego, CA) were calculated from absolute threshold values, from 
3.56 (the lowest threshold response value in the data set) up to the threshold response of each rat 
across time. Decreased AUC reflects an increase in mechanical allodynia. For all studies, the 
AUC measures across time were collapsed into a single timepoint for each animal, thus there is 
not a repeated measurement. For baseline measurements, a two-way ANOVA at that single 
timepoint was the statistic used. For pre-drug statistics, a t-test was performed on the AUC 
values as there were only two groups, sham and SNAP. For statistics during the drug 
administration period, a two-way ANOVA was then performed on the AUC values, with the 
exception of the studies examining the effects of (+)-naltrexone on SNAP. For the (+)-naltrexone 
drug timecourse in Figure 5, a one-way ANOVA was used because it is not a 2x2 design. For the 
study looking at behavior after stopping (+)-naltrexone administration in Figure 6, a t-test was 
used because there are only two groups, SNAP+Vehicle and SNAP+(+)-Naltrexone. The 
appropriate AUC statistic was performed on days 35-63 for Figure 1, days 35-42 for Figure 2, 
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days 35-63 for Figure 3, days 14-28 for Figure 4, days 35-46 for Figure 5, days 29-33 for Figure 
6B, and days 35-42 for Figure 6C. A Bonferroni post hoc test for multiple comparisons was used 
where appropriate. For all tests, p<0.05 was considered statistically significant. 
Results 
Effect of Administering Propentofylline on SNAP 
In this first study, once daily PPF was administered i.p. at 10 mg/kg for 35 days beginning 28 
days post-surgery. No differences were observed between groups in the response thresholds 
recorded for the hindpaw ipsilateral (Fig 2.1A) or contralateral (Fig 2.1B) to the avulsion injury 
pre-surgery [baseline (BL)]. No differences were observed between the SNAP groups on either 
the ipsilateral or contralateral hindpaw pre-drug, recorded 14, 21, and 28 days after surgery; that 
is, prior to initiation of PPF treatment.  PPF had no effect on the response thresholds of sham 
operated rats, which showed mild and transient allodynia compared to avulsion. The SNAP 
group was significantly more allodynic than the sham group pre-drug (days 14-28) on both the 
ipsilateral (t30 = 4.396; p<0.001) and contralateral (t29 = 2.9; p<0.01) hindpaw. The two-way 
ANOVA comparing the AUC of Sham+Vehicle, Sham+PPF, SNAP+Vehicle, and SNAP+PPF 
over the drug treatment timecourse (days 35-63) showed a significant interaction in both the 
ipsilateral (F1,32 = 16.29; p<0.001; Fig 2.1C) and contralateral (F1,32 = 15.78; p<0.001; Fig 2.1D) 
hindpaw. There was also a significant main effect of surgery in both the ipsilateral (F1,32 = 16.57; 
p<0.001) and contralateral (F1,32 = 11.94; p<0.01) hindpaw as well as a significant main effect of 
drug treatment in both the ipsilateral (F1,32 = 8.603; p<0.01) and contralateral (F1,32 = 4.232; 
p<0.05) hindpaw. Bonferroni post hoc analysis of the AUCs revealed that the SNAP+Vehicle 
group was significantly more allodynic than all other groups (p<0.05) in both the ipsilateral and 
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contralateral hindpaw. Furthermore, there were no significant differences between the other three 
groups in both the ipsilateral and contralateral hindpaw (p>0.05).  
Figure 2.1: Effect of administering propentofylline on SNAP 
 
Figure 2.1. Assessment of the effects of propentofylline (PPF) on SNAP. Rats were tested for 
mechanical allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) 
hindpaw. Rats that received PPF (10 mg/kg, i.p.) for 35 days beginning 28 days after surgery 
were significantly less allodynic than rats that received vehicle in both the ipsilateral (C) and 
contralateral (D) hindpaw. Data are presented as mean ± SEM and analyzed using a two-way 
ANOVA on the AUCs, n=6-8/group. *p<0.05 compared to all other groups. 
 
Detailed Timecourse of Administering Propentofylline on SNAP 
Given that PPF was able to reverse SNAP, the next step was to determine how quickly 
PPF reversed the pain. To answer this question and to provide a replication of the full reversal of 
allodynia reported above, PPF was administered for 14 days and tested every 2-4 days over the 
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drug timecourse. No differences were observed between groups in the response thresholds 
recorded for the hindpaw ipsilateral (Fig 2.2A) or contralateral (Fig 2.2B) to the avulsion injury 
pre-surgery [baseline (BL)]. No differences were observed between the SNAP groups on either 
the ipsilateral or contralateral hindpaw pre-drug, recorded 14, 21, and 28 days after surgery; that 
is, prior to initiation of PPF treatment.  PPF had no effect on the response thresholds of sham 
operated rats, which showed mild and transient allodynia compared to SNAP. The SNAP group 
was significantly more allodynic than the sham group pre-drug (days 14-28) on both the 
ipsilateral (t22 = 4.155; p<0.001) and contralateral (t22 = 4.154; p<0.001) hindpaw. The two-way 
ANOVA comparing the AUC of Sham+Vehicle, Sham+PPF, SNAP+Vehicle, and SNAP+PPF 
over the drug treatment timecourse (days 35-42) showed a significant interaction in both the 
ipsilateral (F1,20 = 7.854; p<0.05; Fig 2.2C) and contralateral (F1,20 = 6.996; p<0.05; Fig 2.2D) 
hindpaw. There was also a significant main effect of surgery in both the ipsilateral (F1,20 = 40.65; 
p<0.0001) and contralateral (F1,20 = 67.61; p<0.0001) hindpaw as well as a significant main 
effect of drug treatment in both the ipsilateral (F1,20 = 7.442; p<0.05) and contralateral (F1,20 = 
9.668; p<0.01) hindpaw.  Bonferroni post hoc analysis of the AUCs revealed that 
SNAP+Vehicle group was significantly more allodynic than all other groups (p<0.05) in both the 
ipsilateral and contralateral hindpaw. Furthermore, there were no significant differences between 
the other three groups in both the ipsilateral and contralateral hindpaw (p>0.05). Replicating the 
effects reported above, PPF again completely reversed allodynia, such that response thresholds 
for the SNAP+PPF group were comparable to those of sham controls. 
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Figure 2.2: Detailed timecourse of administering propentofylline on SNAP 
 
Figure 2.2. Detailed timecourse of the effects of PPF on SNAP. Rats were tested for mechanical 
allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) hindpaw. Rats that 
received PPF (10 mg/kg, i.p.) for 14 days beginning 28 days after surgery were significantly less 
allodynic than rats that received vehicle in both the ipsilateral (C) and contralateral (D) hindpaw.  
Data are presented as mean ± SEM and analyzed using a two-way ANOVA on the AUCs, n=6 
per group. *p<0.05 compared to all other groups.  
 
Effect of Administering Ibudilast Late in the Development of SNAP 
To define whether similar results could be achieved using a different putative glial 
activation inhibitor with a distinct mechanism of action, ibudilast was chosen for test. Ibudilast 
was studied here as it is known to have MIF inhibitor and toll like receptor 4 (TLR4) inhibitor 
mechanisms of action for neuropathic pain reversal
264
 beyond its action as a PDE inhibitor.
179
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Ibudilast was administered s.c. once daily at 10 mg/kg for 35 days beginning 28 days post-
surgery. No differences were observed between groups in the response thresholds recorded for 
the hindpaw ipsilateral (Fig 2.3A) or contralateral (Fig 2.3B) to the avulsion injury pre-surgery 
[baseline (BL)]. No differences were observed between the SNAP groups on either the ipsilateral 
or contralateral hindpaw pre-drug, recorded 14, 21, and 28 days after surgery, prior to initiation 
of ibudilast dosing.  Ibudilast had no effect on the response thresholds of sham operated rats, 
which showed mild and transient allodynia compared to SNAP. The SNAP group was 
significantly more allodynic than the sham group pre-drug (days 14-28) on both the ipsilateral 
(t26 = 6.366; p<0.0001) and contralateral (t27 = 3.767; p<0.001) hindpaw. The two-way ANOVA 
comparing the AUC of Sham+Vehicle, Sham+Ibudilast, SNAP+Vehicle, and SNAP+Ibudilast 
over the drug treatment timecourse (days 35-63) showed a significant interaction in both the 
ipsilateral (F1,28 = 11.01; p<0.01; Fig 2.3C) and contralateral (F1,28 = 9.033; p<0.01; Fig 2.3D) 
hindpaw. There was also a significant main effect of surgery in both the ipsilateral (F1,28 = 28.92; 
p<0.0001) and contralateral (F1,28 = 13.03; p<0.01) hindpaw as well as a significant main effect 
of drug treatment in both the ipsilateral (F1,28 = 20.97; p<0.0001) and contralateral (F1,28 = 8.975; 
p<0.01) hindpaw. Bonferroni  post hoc analysis of the AUCs revealed that SNAP+Vehicle group 
was significantly more allodynic than all other groups (p<0.05) in both the ipsilateral and 
contralateral hindpaw. Furthermore, there were no significant differences between the other three 
groups in both the ipsilateral and contralateral hindpaw (p>0.05). 
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Figure 2.3: Effect of administering ibudilast late in the development of SNAP 
 
Figure 2.3. Assessment of the effects of ibudilast administered late in the development of SNAP. 
Rats were tested for mechanical allodynia across a timecourse on both the ipsilateral (A) and 
contralateral (B) hindpaw. Rats that received ibudilast (10 mg/kg, s.c.) for 35 days beginning 28 
days after surgery were significantly less allodynic than rats that received vehicle in both the 
ipsilateral (C) and contralateral (D) hindpaw. Data are presented as mean ± SEM and analyzed 
using a two-way ANOVA on the AUCs, n=6-8 per group. *p<0.05 compared to all other groups. 
 
Effect of Administering Ibudilast Early in the Development of SNAP 
Since two different putative glial activation inhibitors could reverse established chronic 
SNAP, here it was tested whether ibudilast would prove effective when administration began at 
an earlier timepoint after surgery. In order to examine this issue, ibudilast was administered once 
daily s.c. at 10 mg/kg for 21 days beginning 14 days post-surgery. No differences were observed 
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between groups in the response thresholds recorded for the hindpaw ipsilateral (Fig 2.4A) or 
contralateral (Fig 2.4B) to the avulsion injury pre-surgery [baseline (BL)]. Ibudilast had no effect 
on the response thresholds of sham operated rats, which showed mild and transient allodynia 
compared to SNAP. The two-way ANOVA comparing the AUC of Sham+Vehicle, 
Sham+Ibudilast, SNAP+Vehicle, and SNAP+Ibudilast over the drug treatment timecourse (days 
14-35) showed a significant interaction in both the ipsilateral (F1,20 = 12.79; p<0.01; Fig 2.4C) 
and contralateral (F1,20 = 7.268; p<0.05; Fig 2.4D) hindpaw. There was also a significant main 
effect of surgery in both the ipsilateral (F1,20 = 58.24; p<0.0001) and contralateral (F1,20 = 55.06; 
p<0.001) hindpaw as well as a significant main effect of drug treatment in both the ipsilateral 
(F1,20 = 15.18; p<0.001) and contralateral (F1,20 = 10.20; p<0.01) hindpaw. Bonferroni post hoc 
analysis of the AUCs revealed that SNAP+Vehicle group was significantly more allodynic than 
all other groups (p<0.05) in both the ipsilateral and contralateral hindpaw. Furthermore, there 
were no significant differences between the other three groups in the ipsilateral hindpaw 
(p>0.05). While the ipsilateral and contralateral hindpaws of the SNAP+Ibudilast group did not 
statistically differ, the contralateral hindpaw of the SNAP+Ibudilast group, given its tighter 
SEMs, was found to be statistically different from both the Sham+Vehicle group and the 
Sham+Ibudilast group (p<0.05), supportive of a modestly reliable but incomplete reversal of 
allodynia contralaterally.  
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Figure 2.4: Effect of administering ibudilast early in the development of SNAP 
 
Figure 2.4. Assessment of the effects of ibudilast administered early in the development of 
SNAP. Rats were tested for mechanical allodynia across a timecourse on both the ipsilateral (A) 
and contralateral (B) hindpaw. Rats that received ibudilast (10 mg/kg, s.c.) for 21 days beginning 
14 days after surgery were significantly less allodynic than rats that received vehicle in both the 
ipsilateral (C) and contralateral (D) hindpaw. Data are presented as mean ± SEM and analyzed 
using a two-way ANOVA on the AUCs, n=5-6 per group. *p<0.05 compared to all other groups, 
+p<0.05 compared to Sham+Vehicle and Sham+Ibudilast. 
 
Effect of Administering (+)-Naltrexone on SNAP 
The success of ibudilast and PPF, above, raises the question of whether a glial modulator 
with no known PDE activity can also resolve SNAP.   As one of the mechanisms of action of 
ibudilast is as a TLR4 inhibitor,
264
 this  study sought to define whether TLR4 inhibition would be 
sufficient to resolve SNAP. Given that TLR4 is activated by endogenous substances released by 
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cellular stress, damage and death,
26, 142
 inhibition of TLR4 was chosen from the known ibudilast 
mechanisms of action for test here given the neuropathology associated with SNAP. (+)-
Naltrexone was chosen for test as it is a non-opioid, blood-brain barrier permeable, highly 
selective TLR4 antagonist
316
 that has been shown to reverse peripheral neuropathic pain.
144
 Here 
we administered 3x daily (+)-naltrexone s.c. at 6 mg/kg for 14 days beginning 32 days post-
surgery. To extend the detailed timecourse reported for PPF above, behavior was again recorded 
every 3-4 days of (+)-naltrexone dosing so to define the rapidity with which allodynia reversal 
would occur in the absence of PDE inhibition. No differences were observed between groups in 
the response thresholds recorded for the hindpaw ipsilateral (Fig 2.5A) or contralateral (Fig 
2.5B) to the avulsion injury pre-surgery [baseline (BL)]. No differences were observed between 
the SNAP groups on either the ipsilateral or contralateral hindpaw pre-drug recorded 14, 21, 28, 
and 32 days after surgery; that is prior to initiation of (+)-naltrexone dosing.  (+)-Naltrexone had 
no effect on response thresholds of sham operated rats, which showed mild and transient 
allodynia compared to SNAP. The SNAP group was significantly more allodynic than the sham 
group pre-drug (days 14-32) on both the ipsilateral (t16 = 6.928; p<0.0001) and contralateral (t16 
= 7.444; p<0.0001) hindpaw. The one-way ANOVA comparing the AUC of Sham+Vehicle, 
SNAP+Vehicle, and SNAP+(+)-Naltrexone over the drug treatment timecourse (days 35-46) was 
significant in both the ipsilateral (F2,15 = 11.76; p<0.001; Fig 2.5C) and contralateral (F2,15 = 
16.82; p<0.001; Fig 2.5D) hindpaw. Bonferroni p post hoc analysis of the AUCs revealed that 
SNAP+Vehicle group was significantly more allodynic than all other groups (p<0.05) in both the 
ipsilateral and contralateral hindpaw. Furthermore, there were no significant differences between 
the other two groups in both the ipsilateral and contralateral hindpaw (p>0.05).  
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Figure 2.5: Effect of administering (+)-naltrexone on SNAP 
 
Figure 2.5. Assessment of the effects of (+)-naltrexone on SNAP. Rats were tested for 
mechanical allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) 
hindpaw. Rats that received (+)-naltrexone (6 mg/kg, s.c.) for 14 days beginning 32 days after 
surgery were significantly less allodynic than rats that received vehicle in both the ipsilateral (C) 
and contralateral (D) hindpaw. Data are presented as mean ± SEM and analyzed using a one-way 
ANOVA on the AUCs, n=6 per group. *p<0.05 compared to all other groups.  
 
Effect of Ceasing (+)-Naltrexone Administration on SNAP 
 In order to determine whether the reversal of allodynia observed with such glial 
modulators may be sustained after elimination of the drug, a final study was undertaken using 
(+)-naltrexone as a test compound for this purpose. Here we administered 3x daily (+)-
naltrexone s.c. at 6 mg/kg for 6 days beginning 28 days post-surgery, then stopped administering 
the drug after day 33 and continued to record behavior until the rats were back at pre-drug 
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allodynia pain thresholds. No differences were observed between groups in the response 
thresholds recorded for the hindpaw ipsilateral (Fig 2.6A) or contralateral (Fig 2.6B) to the 
avulsion injury pre-surgery [baseline (BL)]. No differences were observed between the SNAP 
groups on either the ipsilateral or contralateral hindpaw pre-drug recorded 14, 21, and 28 days 
after surgery; that is prior to initiation of (+)-naltrexone dosing. The t-test comparing the AUC of 
SNAP+Vehicle and SNAP+(+)-Naltrexone over the drug treatment timecourse (days 29-33) was 
significant in both the ipsilateral (t9 = 3.267; p<0.01; Fig 2.6C) and contralateral (t9 = 2.833; 
p<0.05; Fig 2.6D) hindpaw. The t-test comparing the AUC of SNAP+Vehicle and SNAP+(+)-
Naltrexone over the drug cessation period (days 35-42) was not significant in either the 
ipsilateral (p>0.05; Fig 2.6E) or contralateral (p>0.05; Fig 2.6F) hindpaw. 
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Figure 2.6: Effect of ceasing (+)-naltrexone administration on SNAP 
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Figure 2.6. Assessment of the effects of ceasing (+)-naltrexone on SNAP. Rats were tested for 
mechanical allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) 
hindpaw. Rats that received (+)-naltrexone (6 mg/kg, s.c.) for 6 days beginning 28 days after 
surgery were significantly less allodynic than rats that received vehicle in both the ipsilateral (C) 
and contralateral (D) hindpaw. After stopping (+)-naltrexone administration on day 33, rats that 
were receiving (+)-naltrexone returned to pre-drug allodynia thresholds in both the ipsilateral (E) 
and contralateral (F) hindpaw. Data are presented as mean ± SEM and analyzed using a t-test on 
the AUCs, n=6 per group. *p<0.05 compared to all other groups.  
  
Discussion 
 Here we show that three different putative glial inhibitors with distinct mechanisms of 
action, PPF, ibudilast, and (+)-naltrexone, are all able to reverse SNAP. Thus, converging lines 
of evidence from testing multiple inhibitors commonly assumed to have some glial mechanisms 
of action suggest a role for glia in this phenomenon. Importantly, none of these inhibitors 
reversed allodynia upon first administration, but required multiple days of treatment to achieve 
full reversal. Taken together, these data suggest that treating CNP with inhibitors that have some 
action on glia may prove to be a fruitful strategy for improving clinical pain control in such 
cases. 
One strategy for controlling CNP is increasing cyclic adenosine monophosphate (cAMP) 
by inhibiting phosphodiesterases (PDEs) which hydrolyze cAMP and/or cyclic guanosine 
monophosphate (cGMP).
21
 PDE inhibitors reverse CCI-induced allodynia and hyperalgesia,
325
 
and rolipram has been shown to decrease proinflammatory cytokine levels in TBI
7
 and SCI.
243
 
Further, selective PDE4 inhibitors decrease hindpaw allodynia from compression SCI by 
reducing immune cell infiltration/activation and free radical formation.
11
 PPF is a methyl-
xanthine selective PDE4 inhibitor,
309
 an isoform expressed in both microglia and astrocytes.
195
 
Although neurons express PDE4, PDE4 is the major isoform expressed in immune and 
inflammatory cells.
149
 Further, microglial activation is regulated by PDE4
283
 and PPF decreases 
release of proinflammatory cytokines in microglia.
280
 In addition, systemic PPF decreases both 
49 
 
microglia and astrocyte activation in a rat peripheral neuropathy model.
309
 The present study is 
the first to show that systemic PPF is effective in reversing allodynia in a CNP model. The only 
other neuropathic pain studies using PPF administered it intrathecally in a rat model of 
hemisection SCI, which also reversed mechanical allodynia.
111
 Notably, the half life of PPF and 
its active metabolite is very short, ~1 hr,
309
 therefore the anti-allodynic effects observed in the 
current studies at ~15 hr post administration suggest that persistent intracellular alterations have 
occurred, in keeping with the conclusions of Sweitzer et al.
309
 Studies have shown that increases 
in cAMP results in increases of the anti-inflammatory cytokine IL-10,
3, 77, 290
 including from 
microglia.
357
  Notably, IL-10 has been recognized for its therapeutic potential in SCI.
317, 366
 The 
resulting ratio of decreased proinflammatory signaling to increased anti-inflammatory signaling 
could explain the sustained pain reversal observed even when propentofylline is not present at 
the time of testing.  
 Although ibudilast, like PPF, is a PDE inhibitor (inhibits PDE 1, 2, 3, and 4 in rat),
178
 
PDE inhibition alone cannot account for the anti-inflammatory effects of ibudilast.
49
 Therefore, 
there must be an alternative mechanism.
264
  Ibudilast is now known to also inhibit macrophage 
migration inhibitory factor (MIF)
264
 and is effective in treating SNL,
179
 SCI (present data),
119
 and 
CCI pain.
119
  MIF stimulates the release of IL-1 and TNF and is required for IL-1 and TNF-
induced MAPK activation.
318
 MIF itself is now recognized as a pro-inflammatory cytokine
2
 and 
has been implicated in multiple central neuropathies including stroke,
338
 MS,
116
 TBI,
323
 and 
SCI.
226
 In studies examining the role of MIF in SCI, MIF knock-out mice with compression SCI 
recovered motor function faster than wild-type controls,
226
 and a clinical pilot study found that 
SCI patients with chronic pain had higher levels of serum MIF compared to both non-injured 
controls as well as SCI patients who did not have a history of chronic pain.
301
 It is important to 
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note that these increased circulating levels of MIF were detected long after the initial injury, 
providing evidence that there is enduring release of MIF that could then be sustaining the CNP 
state we observe in SNAP which is reversed by ibudilast administration.  Taken together, these 
studies suggest that since MIF is up-regulated in multiple CNP models, MIF inhibitors are 
potential candidates for successful CNP therapeutics.   
  Another potential CNP treatment that has not been as well studied is (+)-naltrexone, a 
selective TLR4 antagonist, as evidenced by in vivo and in vitro studies as well as in silico 
modeling.
141, 144, 145, 316
 In contrast to PPF and ibudilast, (+)-naltrexone has no known PDE or 
MIF inhibitory actions.  Although we have shown that (+)-naltrexone reverses peripheral CCI 
pain,
144
 no one has shown reversal of CNP using (+)-naltrexone until now.  (+)-Naltrexone is 
unique compared to the (-)-naltrexone isomer in that it does not bind classical µ-opioid 
receptors.
316
 As a result, (+)-naltrexone does not cause many of the undesirable side effects 
observed with many other opiate-based analgesics,
144, 316
 making it a more desirable treatment 
option. Since TLR4 in the CNS is found predominantly on glial cells
141
 and blocking TLR4 
reverses allodynia, it is very likely that the pain reversal seen here after (+)-naltrexone 
administration is glially mediated. Importantly, as observed with PPF and ibudilast, it took 
multiple days of (+)-naltrexone administration to observe full reversal, indicating that acute 
dosing with glial modulators may not be ideal for treating established CNP. In addition, the anti-
allodynic effects of (+)-naltrexone gradually dissipated once the drug was no longer being 
administered, which has also been observed previously for PPF
112
 and ibudilast.
179
 This suggests 
that although these drugs are perhaps able to attenuate glial activation during administration, they 
are not inducing permanent changes that can overcome the proinflammatory environment and 
persistent glial activation caused by the original injury and subsequent central sensitization. 
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One reason that many drugs fail clinically could be that they are not given for a 
sufficiently long duration, and there are examples in the literature of this with all three of the 
drugs tested here. Reversal of spinal nerve ligation (SNL)-induced allodynia failed to occur when 
PPF was administered for only 7 days,
231
 whereas it took 10 days of daily PPF administration to 
both prevent and reverse SNL-induced allodynia.
309
 In the CCI and spinal nerve ligation models, 
only transient pain reversal occurred with one day of systemic ibudilast, and ~5 days of dosing 
was required for full reversal of CCI allodynia.
179
 Similarly, only transient reversal (~1 hr) of 
allodynia occurs with a single intrathecal injection of (+)-naltrexone, whereas chronic intrathecal 
infusion of (+)-naltrexone completely reversed allodynia only when administered for 4 days.
144
 
In the current studies it took multiple days of systemic administration to achieve significant 
allodynic reversal with all 3 of the drugs tested, which suggests that had these drugs been 
administered as a single injection or for only a couple of days they would have failed.
342
  
Furthermore, treatments are often more effective if they are administered early on in pain 
development. For instance, disease modifying anti-rheumatic drugs for rheumatoid arthritis are 
only effective for treating pain and other symptoms if administered within the first three months 
symptoms appear.
184
 Another example of successful early pharmacological intervention is in 
migraine patients, where administering triptans within the first 20-120 minutes after symptom 
onset can actually prevent allodynia from developing.
29
 Unfortunately, there are many cases 
where pain patients do not or are not able to seek treatment until they have been in chronic pain 
for months.  Thus, it is important to find therapeutics that are effective not only when 
administered upon first pain development but also after the symptoms have become chronic. 
Here we gave ibudilast in the early stages of pain development as well as in a later stage of 
chronic pain development, and saw complete reversal of allodynia in both cases. These data 
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suggest that glia are likely involved both in the early stages of neuropathic pain development as 
well as the long-term maintenance of chronic neuropathic pain, and that at least ibudilast has the 
potential to treat patients at various stages of their pain progression. Ibudilast has recently been 
identified as a toll-like receptor 4 (TLR4) antagonist
145
 (Johnson, unpub. obs., 2012), and 
ibudilast as well as PPF and (+)-naltrexone were able to treat below-level contralateral pain as 
well, increasing their attractiveness as therapeutics. 
Although the studies here focus on the glial mechanisms underlying CNP, we cannot rule 
out the fact that neurons and other cell types are also likely involved. Chew et al. report 
increased ipsilateral bilateral glial activation in the dorsal horn following L3-L6 dorsal root 
avulsion
46
 and increased ipsilateral mechanical hypersensitivity following L5 dorsal and ventral 
root avulsion,
47
 which lends support to what we observe in the current studies. However, they 
also report significant increases in bilateral infiltrating macrophages in the dorsal horn, which 
could also be helping to maintain the neuropathic pain.
46, 47
 Inhibiting AMPA receptors 
attenuates mechanical allodynia and neuronal hyperexcitability following SCI.
113
 In addition, 
injecting NMDA near a SCI contusion injury site delays functional recovery
84
 and administering 
NMDA antagonists shortly after SCI can improve functional recovery and increase pain 
thresholds.
162
 A recent study found that co-administering PPF and a neuronal NMDA receptor 
inhibitor had additive effects on attenuating peripherally induced-chronic pain.
215
 It is thought 
that MIF triggers ERK/NMDA dependent plasticity in sensory neurons
2
 and it has been shown 
that ibudilast suppresses apoptosis in nerve cells during ischemic brain injury.
180
 Lastly, there are 
studies that report that TLR4 is expressed in primary sensory neurons and can contribute to 
neuropathic pain.
70  
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Since the drugs used here were administered systemically and are putative glial 
inhibitors, we recognize that their actions may not be exclusively on glia and could be interacting 
with other cell types, including resident peripheral immune cells or cells recruited to the injured 
spinal tissue. PPF suppresses the production of TNF-α154 and reactive oxygen species in 
macrophages,
9
, and can also counteract neutrophil activation by blocking the removal of 
adenosine.
363
 Both PPF and ibudilast can prevent kainite-induced cell death in 
oligodendroglia,
358
 and ibudilast can also inhibit platelet aggregation in the presence of 
endothelial cells.
259
 Furthermore, ibudilast reduces inflammatory cell infiltration into the dorsal 
spinal cord in EAE,
99
 which could also be happening in SNAP, along with attenuating resident 
microglial activation. Since TLR4 can also be expressed on neurons
70
 and peripheral
182, 203
 or 
recruited immune cells,
286
 (+)-naltrexone could be exerting some effects on these cells as well. 
Since we use a pain model of central origin and multiple pain studies using these compounds 
suggest the anti-allodynic effects are glially mediated,
119, 144, 179, 252, 309, 314, 346
 it is likely that these 
drugs exert at least some of their anti-allodynic effects by inhibiting glial activation. However, 
these observations highlight the importance of considering the contributions of neurons, 
peripheral/infiltrating immune cells, and glia to CNP. 
In conclusion, it is clear that glia play an important role in the pathogenesis of CNP. We 
were able to show, using our dorsal root avulsion model of SCI (SNAP), that administering 
putative glial inhibitors reverses SCI-induced allodynia both at the onset of pain as well as after 
chronic neuropathic pain had developed, although it takes at least a week of daily dosing to 
achieve full reversal. Treating CNP with inhibitors that have some mechanistic action on glial 
cells has the potential to optimize treatment and dramatically increase the quality of life for 
thousands of chronic pain patients.    
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Abstract 
Central neuropathic pain (CNP) is a debilitating outcome of spinal cord injury (SCI) and 
current treatments are ineffective. A growing body of literature suggests that activating 
adenosine A2A receptors (A2ARs) decreases the release of proinflammatory cytokines and 
increases the release of anti-inflammatory cytokines. We investigated the effects of 
administering intrathecal (i.t.) A2AR agonists on CNP by measuring hindpaw mechanical 
allodynia in a rat model of SCI termed spinal neuropathic avulsion pain (SNAP). Other models 
of SCI cause extensive damage to the spinal cord, which cause paralysis and health problems. 
SNAP rats with unilateral T13/L1 avulsion do not have motor or health problems and develop 
below-level bilateral allodynia. A single i.t. injection of the A2AR agonist 2-p-(2-
carboxyethyl)phenethylamino-5’-N-ethylcarboxamido adenosine HCl (CGS21680) reversed 
SCI-induced allodynia for at least 6 weeks. The reversal is in part mediated by interleukin (IL)-
10, as administering neutralizing IL-10 antibodies 1 week after CGS21680 abolished the anti-
allodynic effect of CGS21680. Dorsal spinal cord tissue from the ipsilateral site of SCI (T13/L1) 
was assayed 1 week and 6 weeks after CGS21680 for IL-10, CD11b, and TNF-α gene 
expression. CGS21680 treatment did not change IL-10 gene expression but did significantly 
decrease CD11b and TNF-α gene expression at both timepoints. A single i.t. injection of another 
A2AR agonist, 4-(3-(6-amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-
9H-purin-2-yl)prop-2-ynyl)piperidine-1-carboxylic acid methyl ester (ATL313), was also able to 
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significantly prevent and reverse SCI-induced allodynia. The enduring pain reversal after a 
single i.t. injection of A2AR agonists suggests that A2AR agonists could be exciting new 
candidates for treating SCI-induced CNP.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Introduction 
Central neuropathic pain is a common and debilitating consequence of spinal cord injury 
(SCI). More than 66% of people with SCI develop chronic pain,
289
 and of that population ~30% 
develop below-level central neuropathic pain.
288
 Below-level pain is defined as pain occurring at 
least 2 dermatomes away from the original injury. Patients with below-level pain describe their 
pain as severe,
353
 and current pharmacotherapies for treating central neuropathic pain aren’t 
effective, with only ~50% pain relief in 1 out of 2-3 people.
16
 We developed a dorsal root 
avulsion animal model we termed spinal neuropathic avulsion pain (SNAP) to study SCI-induced 
central neuropathic pain. Current animal models of SCI, such as contusion and hemisection, 
cause extensive damage to the spinal cord and animals develop paralysis, urinary tract infections, 
and autotomy, which can complicate assessments of pain behavior. SNAP rats do not have 
compromised motor function or health problems and unilateral T13/L1 avulsion induces robust, 
reliable, bilateral below-level mechanical allodynia.
349
  
It is known that spinal glia (microglia, astrocytes) play a key role in facilitating chronic 
pain states in animal models of peripheral neuropathic pain.
343
 During an inflammatory event, 
glia become activated and release neuroexcitatory substances that include proinflammatory 
cytokines, which drive neuropathic pain.
208
 Recent studies have shown that glia are activated in 
models of SCI including hemisection
112
 and contusion,
312
 and persistent glial activation can both 
induce and maintain below-level SCI neuropathic pain.
137
 Conversely, glial cells can also release 
anti-inflammatory mediators that attenuate neuropathic pain.
206
 Pharmacological therapies that 
modulate glia in such a way that they express a less proinflammatory phenotype could prove to 
be an ideal treatment for central neuropathic pain in SCI. 
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Adenosine is an endogenous substance in the central nervous system (CNS) and can bind 
4 different G protein-coupled receptors: adenosine 1 receptor (A1R), A2AR, A2BR, and A3R.
275
 
A2ARs are unique because they are found not only on neurons, but on immune cells in the 
peripheral and central nervous systems.
58
 The anti-inflammatory effects of adenosine are 
generally attributed to occupancy of the A2A receptor,
125
 and there is an expanding body of 
literature that documents the ability of A2AR agonists to decrease inflammation by suppressing 
proinflammatory cytokines and increasing anti-inflammatory cytokines in peripheral
125
 and 
central
191, 192
 immune cells. Furthermore, a single intrathecal (i.t.) administration of either of two 
different A2AR agonists (CGS21680, ATL313) reversed peripheral neuropathy-induced allodynia 
for more than 4 weeks.
191
 Whether or not this enduring reversal from a single administration of 
an A2AR agonist can also be observed in a model of central neuropathic pain, and what the 
mechanisms might be, is currently unknown. The aim of this study was to provide an initial 
characterization of A2AR agonism and potential underlying mechanisms in central neuropathic 
pain. 
Our hypothesis was that A2AR agonists would attenuate SNAP by decreasing glial 
activation and subsequent release of proinflammatory cytokines while also increasing the release 
of anti-inflammatory cytokines. Therefore, our first goal was to administer CGS21680 at a single 
timepoint and record a behavioral timecourse and then attempt to block the anti-allodynic effect. 
We next wanted to determine whether there were changes in pro- and anti-inflammatory gene 
expression in the spinal cord at different timepoints following CGS21680 administration. Lastly, 
we wanted to define whether the effects were either agonist or timing-specific. Thus, we 
administered another A2AR agonist, ATL313, both early and late in the development of SNAP.   
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Materials and Methods 
 
Animals 
Pathogen-free male Sprague-Dawley rats (325-350g; Harlan Laboratories, Madison, WI, 
USA) were used for all experiments. Rats were pair-housed prior to surgery and then single-
housed after surgery with standard rat chow and water available ad libitum. Housing was in a 
temperature-controlled room that was maintained at 23+/-2°C with a 12 hr light/dark cycle 
(lights on at 0700 hr). The rats were allowed a minimum of 1 week to habituate to the colony 
room before initiating the experiment. All procedures were performed during the light cycle. 
Following surgery, the animals were singly housed. All protocols were approved by the 
University of Colorado at Boulder Institutional Animal Care and Use Committee.  
Drugs 
The A2AR agonist 2-p-(2-carboxyethyl)phenethylamino-5’-N-ethylcarboxamido 
adenosine HCl (CGS21680) was purchased from Sigma-Aldrich (St Louis, MO, USA). The 
A2AR agonist 4-(3-(6-amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-
purin-2-yl)prop-2-ynyl)piperidine-1-carboxylic acid methyl ester (ATL313) was a gift from 
PGxHealth, a division of Clinical Data (New Haven, CT, USA).  All drugs were dissolved in 
100% DMSO to create a 10 mΜ stock solution and were stored at -20°C. Fresh aliquots were 
diluted in sterile endotoxin-free isotonic saline (Abbott Laboratories, Abbott Park, IL, USA). The 
vehicle for all drugs was 0.01% DMSO saline solution given the dilution of the drugs from stock 
was 1:10,000 to yield a 10 µΜ dose for CGS2160 and a 1 µΜ dose for ATL313, based on our 
past studies of their relative efficacies in reversing pain induced by peripheral neuropathy.
191, 192
 
All vehicle injections were administered equivolume to CGS21680 and ATL313. Rat IL-10 
neutralizing antibodies were raised in sheep at the National Institute of Biological Standards and 
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Control (South Mimms, Hertfordshire, UK), purified by Avigen (Alameda, CA, USA), and 
administered in saline. An equal dose of normal sheep IgG in saline (Sigma-Aldrich, St Louis, 
MO, USA) was used as the control. 
Spinal Neuropathic Avulsion Pain (SNAP) Surgery 
Unilateral (left) T13/L1 dorsal root avulsion was performed under isoflurane anesthesia. 
Briefly, laminectomy was performed at the T12 vertebral level and the dura mater was incised 
over the dorsal root entry zone. The T13 and L1 dorsal rootlets were carefully isolated and then 
clamped at the dorsal root entry zone and briskly pulled out (avulsed). The dura was then sutured 
closed with sterile 6-0 silk. Sterile saline-moistened surgical sponge was placed over the exposed 
spinal cord to protect it, the muscle was sutured in layers with sterile 3-0 silk, and the skin was 
closed with stainless steel wound clips. Immediately following surgery, rats were single-housed 
in a cage with foam padding for a few hours to protect their spinal cord from further trauma due 
to the brief ataxic period that follows recovery from anesthesia. Sham operated animals were 
treated identically, including dura suturing, except for avulsing of the rootlets. Combi-Pen-48 
antibiotic (Bimeda, Inc., Le Sueur, MN, USA) was administered at the time of surgery and daily 
for 4 days after surgery. 
Acute intrathecal (i.t.) injections 
Rats were anesthetized for no more than 5 min under isoflurane. The lumbar region was 
shaved and cleaned with 70% EtOH. A sterile 18 gauge guide needle with the hub removed was 
inserted into the L5/L6 vertebral space. A PE-10 catheter was inserted into the guide needle, pre-
marked such that the proximal end of the PE-10 tubing rested over L4–L6 lumbar spinal cord. 
All drugs were administered over 20 s (1 µl of drug followed by 2 µl of sterile saline flush) with 
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a 30 s delay before removing the catheter and guide needle. No animals incurred observable 
neurological damage from the procedure. 
Low Threshold Mechanical Allodynia Testing 
 
Prior to surgery, rats were habituated to the testing environment for 4 consecutive days 
prior to recording of behavioral responses. All von Frey assessments were performed blind with 
respect to drug and surgery assignments.  Assessment of von Frey thresholds occurred before 
surgery (baseline) and across a timecourse beginning two weeks after surgery. The von Frey test 
was performed on the plantar surface of each hind paw as previously described in detail.
205
 A 
logarithmic series of 10 calibrated Semmes–Weinstein monofilaments (Stoelting) were 
sequentially applied to the left and right hind paws in random order, each for 8 s at constant 
pressure to determine the stimulus intensity threshold stiffness required to elicit a paw 
withdrawal response. Log stiffness of the hairs is determined by log10 (milligrams x10). The 
range of monofilaments used in these experiments (0.407–15.136 g) produces a logarithmically 
graded slope when interpolating a 50% response threshold of stimulus intensity (expressed as 
log10 (milligrams x10)).
41
 The stimulus intensity threshold to elicit a paw withdrawal response 
was used to calculate the 50% paw withdrawal threshold (absolute threshold) using the 
maximum-likelihood fit method to fit a Gaussian integral psychometric function.
124
 This method 
normalizes the withdrawal threshold for parametric analyses.
124
 SNAP rats require a 2 week 
recovery period after surgery before reliable von Frey testing can begin. 
Processing of tissue for PCR 
RNA isolation and cDNA synthesis.  Total RNA from the 5 mm piece of the T13/L1 
thoracic spinal cord was extracted using the standard phenol/chloroform extraction with TRIzol 
Reagent (Invitrogen) according to the manufacturer’s guidelines. Total RNA was reverse 
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transcribed into cDNA using Superscript II First-Strand Synthesis System (Invitrogen). First-
strand cDNA was synthesized using total RNA, random hexamer primer (5 ng/µl) and 1 mM 
dNTP mix (Invitrogen) and incubated at 65°C for 5 min. After 2 min incubation on ice, a cDNA 
synthesis buffer (5 x reverse transcription (RT) buffer; Invitrogen) and dithiothreitol (10 mM) 
was added and incubated at 25°C for 2 min. Reverse transcriptase (Superscript II; 200 U; 
Invitrogen) was added to a total volume of 20 µl and incubated for 10 min at 25°C, 50 min at 
42°C, and deactivating the enzyme at 70°C for 15 min. cDNA was diluted twofold in nuclease-
free water and stored at -80°C until real-time PCR (RT-PCR) was performed. 
RT-PCR.  Primer sequences were obtained from the GenBank at the National Center for 
Biotechnology Information (www.ncbi.nlm.nih.gov) and are displayed in Table 3.1. Primers 
were generated to span an intron to eliminate genomic interference. Amplification of the cDNA 
was performed, in a blinded procedure, using Quantitect SYBR Green PCR kit (QIAGEN) in 
iCycler iQ 96-well PCR plates (Bio-Rad) on a MyiQ single Color Real-Time PCR Detection 
System (Bio-Rad). The reaction mixture (26 µl) was composed of Quanti-Tect SYBR Green 
(containing fluorescent dye SYBR Green I, 2.5 mM MgCl2, dNTP mix, and Hot Start Taq 
polymerase), 10 nM fluorescein, 500 nM each forward and reverse primer (Invitrogen), 
nuclease-free water, and 1 µl of cDNA from each sample. Each sample was measured in 
duplicate. The reactions were initiated with a hot start at 95°C for 25 min, followed by 40 cycles 
of 15 s at 94°C (denaturation), 30 s at 55–60°C (annealing), and 30 s at 72°C (extension). Melt 
curve analyses were conducted to assess uniformity of product formation, primer–dimer 
formation, and amplification of nonspecific products. The PCR product was monitored in real-
time, using the SYBR Green I fluorescence, using the MyiQ Single-Color Real-Time PCR 
Detection System (Bio-Rad). Threshold for detection of PCR product was set in the log-linear 
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phase of amplification and the threshold cycle (CT) was determined for each reaction. The level 
of the target mRNA was quantified relative to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) using the comparative CT (ΔCT) method. The expression of 
GAPDH was not significantly different between treatments. 
 Table 3.1. Primer Sequences  
Gene   Primer Sequence (5′-3′)    GenBank accession no. 
GAPDH (i-s)  TCTTCCAGGAGCGAGATCGC (forward)   NG_028301.1 
                          TTCAGGTGAGCCCCAGCCTT (reverse) 
 
IL-10 (i-s)  GGACTTTAAGGGTTACTTGGG (forward)  NM_012854.2 
AGAAATCGATGACAGCGTCG (reverse) 
___________________________________________________________________________________________ 
CD11b (i-s)  CTGGTACATCGAGACTTCTC (forward)   NM_012711.1 
 TTGGTCTCTGTCTGAGCCTT (reverse) 
 
TNF-α (i-s)  CAAGGAGGAGAAGTTCCCA (forward)   NM_012675.3 
 TTGGTGGTTTGCTACGACG (reverse) 
  
i-s, intron-spanning primers generated to reduce genomic interference 
 
Pharmacological Manipulations 
Effect of administering the A2AR agonist CGS21680 on SNAP-induced mechanical 
allodynia  
Baseline measures on the von Frey test were collected prior to surgery. SNAP or sham 
surgery was performed and behavioral responses to a mechanical stimulus were recorded 2, 3, 
and 4 weeks post-surgery. At 4 weeks post-surgery, one acute i.t. injection of CGS21680 or 
equivolume vehicle was administered (n = 6-8 per group). Behavioral testing occurred once a 
week for 6 weeks after drug treatment.  
Effect of administering neutralizing IL-10 antibody on the CGS21680 effect in SNAP 
allodynia  
SNAP was conducted and behavioral responses to mechanical stimuli were tested as 
described above. At 4 weeks post-surgery, an acute i.t. administration of CGS21680 (10 µM) or 
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equivolume vehicle was administered. One week later, a single i.t. injection of either sheep anti-
rat neutralizing IL-10 IgG antibodies (0.2 µg/ml; 10 µl) or equivolume and equidose sheep IgG 
(0.2 µg/ml; 10 µl) was administered (n = 9 rats per group). Behavioral responses were measured 
1, 2, 3, 6, 24, 48 h, and 1, 2, and 3 weeks after drug administration. 
Effect of administering the A2AR agonist CGS21680 on gene expression 
 CD11b, IL-10, and TNF-α were chosen for analysis because pilot and published studies 
from our lab,
191
 as well as in the literature,
72, 232, 333
 identify these markers as being specifically 
modulated by A2AR agonists. After recording behavioral responses at the 1 week or 6 week post-
drug treatment timepoint, SNAP rats and a group of naïve control rats were overdosed with 
sodium pentobarbital (0.8 ml) and transcardially perfused with ice-cold 0.9% saline for 2 min. 
The spinal cord was dissected and a 5 mm piece of ipsilateral dorsal spinal cord, with the 
meninges removed, was dissected out to include the T13/L1 spinal level. All tissue was flash 
frozen in liquid nitrogen. Samples were then stored at -80°C until analysis. 
Effect of administering the A2AR agonist ATL313 on SNAP-induced mechanical 
allodynia  
SNAP or sham surgery was conducted and behavioral responses to mechanical stimuli 
were tested as described above. At either 1 week or 7 weeks post-surgery, one acute i.t. injection 
of ATL313 (1 µM) or equivolume vehicle was administered (n = 6-7 per group). Behavioral 
testing occurred once a week for the duration of the experiment. 
Statistical Analysis 
All data were analyzed using GraphPad Prism version 5.04 for Windows Vista 
(GraphPad Software, San Diego, CA, USA). Ipsilateral and contralateral behavioral data were 
analyzed individually. Behavioral measures were normalized as described above and analyzed 
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using unpaired t-test or repeated-measures two-way ANOVA with time and treatment as main 
effects. The RT-PCR data was analyzed using a one-way ANOVA. Bonferroni post hoc tests 
were used where appropriate, and p < 0.05 was considered statistically significant. 
Results 
Effect of administering the A2AR agonist CGS21680 on SNAP-induced mechanical 
allodynia  
In this first study, a single i.t. injection of 10 µM CGS21680 was administered 4 weeks 
post-SNAP or sham surgery. This timepoint was chosen because SNAP rats have been stably 
allodynic for at least 2 weeks and sham rats are no longer allodynic from the intense traumatic 
nature of the sham surgery. No differences were observed between groups in the response 
thresholds recorded for the hindpaw ipsilateral (Fig 3.1A) or contralateral (Fig 3.1B) to the 
avulsion injury pre-surgery [baseline (BL)]. CGS21680 had no effect on the response thresholds 
of sham operated rats. The two-way repeated measures ANOVA from the time of injection (4 
weeks post-SNAP) until the end of the experiment (10 weeks post-SNAP) showed a significant 
interaction in both the ipsilateral (F15,105 = 1.776; p<0.05; Fig. 3.1A) and contralateral (F15,105 = 
2.258; p<0.01; Fig. 3.1B) hindpaw. There was also a significant main effect of time in both the 
ipsilateral (F5,105 = 13.56; p<0.0001) and contralateral (F5,105 = 5.823; p<0.0001) hindpaw as well 
as a significant main effect of drug treatment in both the ipsilateral (F3,105 = 80.42; p<0.0001) 
and contralateral (F3,105 = 64.81; p<0.0001) hindpaw. Bonferroni post hoc analysis revealed that 
SNAP+Vehicle group was significantly more allodynic than all other groups (p<0.05) in both the 
ipsilateral and contralateral hindpaw. Furthermore, there were no significant differences between 
the other three groups in both the ipsilateral and contralateral hindpaw (p>0.05).  
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Figure 3.1: Effect of administering the A2AR agonist CGS21680 on SNAP  
 
 Figure 3.1. Assessment of the effects of administering CGS21680 on SNAP. Rats were tested 
for mechanical allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) 
hindpaw. SNAP rats that received a single i.t. injection of CGS21680 (10 µM) 4 weeks after 
surgery were significantly less allodynic than SNAP rats that received vehicle in both the 
ipsilateral (A) and contralateral (B) hindpaw. CGS21680 had no effect on sham rats. Data are 
presented as mean ± SEM and analyzed using a repeated measures two-way ANOVA, n= 6 per 
group. *p<0.05 compared to all other groups.   
 
Effect of administering neutralizing IL-10 antibody on the CGS21680 effect in SNAP 
allodynia  
Based on previous work in our lab showing the involvement of IL-10 in this 
mechanism,
191
 which was done in a peripheral neuropathic pain model (CCI), we wanted to 
define if IL-10 was involved in a central neuropathic pain model. A single i.t. injection of 
CGS21680 (10 µM) was administered 4 weeks post-SNAP (shams were not included in this 
study because we know that CGS21680 has no effect on sham rats) to parallel the above study. 
One week later, a single i.t. injection of sheep anti-rat neutralizing IL-10 IgG antibodies (0.2 
µg/ml; 10 µl) or control IgG was administered and rats were tested over a timecourse for 
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mechanical allodynia. No differences were observed between groups in the response thresholds 
recorded for the hindpaw ipsilateral (Fig 3.2A) or contralateral (Fig 3.2B) to the avulsion injury 
pre-surgery [baseline (BL)]. CGS21680 significantly decreased pain thresholds (4-5 week 
timepoint) in both the ipsilateral (t34 = 8.648; p<0.0001) and contralateral (t34 = 9.696; p<0.0001) 
hindpaw. The two-way repeated measures ANOVA from the time of anti-IL-10 injection (5 
weeks post-SNAP) until the end of the experiment (3 weeks post-anti-IL-10 inj.) showed a 
significant interaction in both the ipsilateral (F8,128 = 7.224; p<0.0001; Fig. 3.2A) and 
contralateral (F8,128 = 5.638; p<0.0001; Fig. 3.2B) hindpaw. There was also a significant main 
effect of time in both the ipsilateral (F8,128 = 10.82; p<0.0001) and contralateral (F8,128 = 7.354; 
p<0.0001) hindpaw as well as a significant main effect of drug treatment in the ipsilateral (F1,128 
= 7.676; p<0.05) but not the contralateral (p>0.05) hindpaw. Bonferroni post hoc analysis 
revealed that the groups were significantly different beginning 4 hr post-anti-IL-10 injection 
through the 48 hr timepoint post-anti-IL-10 injection in both the ipsilateral (p<0.01) and 
contralateral (p<0.05) hindpaw. 
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Figure 3.2: Effect of administering neutralizing IL-10 antibody on the CGS21680 effect in 
SNAP  
 
Figure 3.2. Assessment of the effects of administering anti-IL-10 on CGS21680-reversed SNAP 
rat allodynia. Rats were tested for mechanical allodynia across a timecourse on both the 
ipsilateral (A) and contralateral (B) hindpaw. SNAP rats that received a single i.t. injection of 
anti-IL-10 (0.2 µg/ml; 10 µl) 1 week after a single i.t. CGS21680 were significantly more 
allodynic than SNAP rats that received vehicle in both the ipsilateral (A) and contralateral (B) 
hindpaw. Data are presented as mean ± SEM and analyzed using a repeated measures two-way 
ANOVA, n= 9 per group, *p<0.05.   
 
Effect of administering the A2AR agonist CGS21680 on mRNA gene expression 
Since neutralizing IL-10 significantly abolished the anti-allodynic effect of CGS21680, 
we next wanted to look at the mRNA gene expression profile at two different timepoints 
following CGS21680 of the anti-inflammatory cytokine IL-10 as well as the microglial 
activation marker CD11b and the proinflammatory cytokine TNF. We chose these specific 
markers because they are known to be modulated by A2AR agonists as stated above. CGS21680 
did not significantly increase IL-10 mRNA in the ipsilateral T13/L1 dorsal spinal cord at either 
the 1 week (p>0.05; Fig. 3.3A) or 6 week (p>0.05; Fig. 3.3B) timepoint post-injection. 
CGS21680 did significantly decrease CD11b mRNA at both the 1 week (F2,20 = 12.99; p<0.001; 
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Fig. 3.3C) and 6 week (F2,14 = 8.123; p<0.01; Fig. 3.3D) timepoint post-injection. Bonferroni 
post hoc analysis revealed that CD11b mRNA was significantly increased in the SNAP+Vehicle 
group (p<0.01) at both timepoints compared to the other 2 groups. CGS21680 also significantly 
decreased TNF-α mRNA at both the 1 week (F2,21 = 9.251; p<0.01; Fig. 3.3E) and 6 week (F2,17 
= 19.32; p<0.0001; Fig. 3.3F) timepoint post-injection. Bonferroni post hoc analysis revealed 
that TNF mRNA was significantly increased in the SNAP+Vehicle group (p<0.05) at both 
timepoints compared to the other 2 groups. 
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Figure 3.3: Effect of administering the A2AR agonist CGS21680 on mRNA gene expression 
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Figure 3.3. Assessment of the effects of administering CGS21680 on mRNA gene expression in 
the T13/L1 dorsal spinal cord. CGS21680 did not significantly increase IL-10 mRNA at either 
the 1 week (A) or 6 week (B) timepoint post-injection. CGS21680 significantly decreased 
CD11b mRNA at both the 1 week (C) and 6 week (D) timepoint post-injection. CGS21680 also 
significantly decreased TNF mRNA at both the 1 week (E) and 6 week (F) timepoint post-
injection. Data are presented as mean ± SEM and analyzed using a one-way ANOVA, n= 6 to 9 
per group. *p<0.05 compared to all other groups.   
 
Effect of administering the A2AR agonist ATL313 on SNAP-induced mechanical 
allodynia  
Lastly, we wanted to test the efficacy of another A2AR agonist, ATL313, on SNAP-
induced allodynia. ATL313 was provided as a gift (Dr. J. Rieger) and was not available for use 
when the previous studies using CGS21680 were undertaken. ATL313 was administered either 
early in the development of SNAP or after SNAP had been maintained for at least 6 weeks. No 
differences were observed between groups in the response thresholds recorded for the hindpaw 
ipsilateral (Fig 3.4A,C) or contralateral (Fig 3.4B,D) to the avulsion injury pre-surgery [baseline 
(BL)]. CGS21680 had no effect on the response thresholds of sham operated rats, which showed 
mild and transient allodynia compared to SNAP. When ATL313 was administered 1 week post-
SNAP, the two-way repeated measures ANOVA from 1 week after the injection (2 weeks post-
SNAP) until the end of the experiment (9 weeks post-SNAP) showed a significant interaction in 
both the ipsilateral (F21,147 = 2.551; p<0.001; Fig. 3.4A) and contralateral (F21,140 = 2.175; p<0.01; 
Fig. 3.4B) hindpaw. There was also a significant main effect of time in both the ipsilateral (F7,147 
= 6.212; p<0.0001) and contralateral (F7,140 = 4.627; p<0.001) hindpaw as well as a significant 
main effect of drug treatment in both the ipsilateral (F3,147 = 27.85; p<0.0001) and contralateral 
(F3,140 = 15.53; p<0.0001) hindpaw. Bonferroni post hoc analysis revealed that SNAP+Vehicle 
group was significantly more allodynic than all other groups (p<0.05) in both the ipsilateral and 
contralateral hindpaw from 3-9 weeks post-ATL313 injection. Furthermore, there were no 
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significant differences between the other three groups in both the ipsilateral and contralateral 
hindpaw (p>0.05). When ATL313 was administered 7 weeks post-SNAP, the two-way repeated 
measures ANOVA from 1 week after the injection (8 weeks post-SNAP) until the end of the 
experiment (9 weeks post-SNAP) showed a significant interaction in both the ipsilateral (F3,120 = 
3.948; p<0.05; Fig. 3.4C) and contralateral (F3,20 = 6.649; p<0.01; Fig. 3.4D) hindpaw. There 
was also a significant main effect of time in both the ipsilateral (F1,20 = 4.451; p<0.05) and 
contralateral (F1,20 = 15.92; p<0.001) hindpaw as well as a significant main effect of drug 
treatment in both the ipsilateral (F3,20 = 20.56; p<0.0001) and contralateral (F3,20 = 7.364; 
p<0.01) hindpaw. Bonferroni post hoc analysis revealed that SNAP+Vehicle group was 
significantly more allodynic than all other groups (p<0.01) in the ipsilateral hindpaw from 8-9 
weeks post-ATL313 and only at 8 weeks post-ATL313 injection (p<0.05) in the contralateral 
hindpaw. Furthermore, there were no significant differences between the other three groups in 
both the ipsilateral and contralateral hindpaw (p>0.05). 
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Figure 3.4: Effect of administering the A2AR agonist ATL313 on SNAP 
Figure 3.4. Assessment of the effects of administering ATL313 on SNAP. Rats were tested for 
mechanical allodynia across a timecourse on both the ipsilateral (A,C) and contralateral (B,D) 
hindpaw. SNAP rats that received a single i.t. injection of ATL313 (1 µM) 1 week after surgery 
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were significantly less allodynic than SNAP rats that received vehicle in both the ipsilateral (A) 
and contralateral (B) hindpaw. ATL313 had no effect on sham rats. SNAP rats that received a 
single i.t. injection of ATL313 (1 µM) 7 weeks after surgery were significantly less allodynic 
than SNAP rats that received vehicle in both the ipsilateral (C) and contralateral (D) hindpaw. 
ATL313 had no effect on sham rats. Data are presented as mean ± SEM and analyzed using a 
repeated measures two-way ANOVA, n= 6 per group. *p<0.05 compared to all other groups. 
 
Discussion 
The present series of studies demonstrate that SNAP SCI creates a profound mechanical 
allodynia below the spinal level of the injury that was resolved by i.t. delivery of an A2AR 
agonist. A single i.t. injection of the A2AR agonists CGS21680 and ATL313 administered weeks 
after surgery reversed SNAP-induced below-level central neuropathic pain for up to 6 weeks, 
and this is at least partially mediated by IL-10. The fact that A2AR agonists are able to reverse 
established central neuropathic pain (4-7 weeks post-SCI) is important mechanistically, as it 
implies that A2AR sensitive pathways remain importantly involved in the long term maintenance 
of the pain, suggestive that A2ARs may prove to be a realistic therapeutic target for clinical pain 
control. This is the first time anyone has shown a long-lasting, single injection A2AR agonist-
induced reversal of central neuropathic pain; most pharmacological therapies require multiple 
days of systemic dosing to reverse neuropathic pain. In addition to reversing SNAP SCI-induced 
allodynia in the present experiments, treatment with CGS21680 also significantly decreased 
mRNA expression of the microglial activation marker CD11b and the proinflammatory cytokine 
TNF-α at both 1 and 6 weeks following CGS21680 administration. 
  The effects of A2AR agonism observed in the present studies are likely due in part to 
suppression of microglial activation and the subsequent release of TNF-α, leading to a shift in 
the microenvironment of the spinal cord from proinflammatory to more anti-inflammatory. It is 
known that anti-inflammatory cytokines attenuate neuropathic pain,
207
 and also that certain 
therapies, such as IL-10 gene therapy, can shift CNS cells from classically activated (more 
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proinflammatory) to alternatively activated (less proinflammatory).
296
 Other studies have shown 
that A2AR agonists decrease TNF-α in spinal cord glia,
101
 monocytes and macrophages,
214
 and 
CSF cells,
191
 as well as decrease both microglial and astrocyte activation in the spinal cord dorsal 
horn following nerve injury.
191
 Taken together, these data suggest that the ability of A2AR 
agonists to reduce inflammation is partially responsible for the long-lasting reversal of SNAP-
induced allodynia. 
A2AR agonists are also known to potentiate the production of the anti-inflammatory 
cytokine IL-10 in vivo.
191
 IL-10 is neuroprotective in SCI and can delay the onset of SCI-induced 
pain behavior,
1
 as well as reduce TNF-α production.20 Here we administered a neutralizing IL-10 
antibody (anti-IL-10) 1 week after CGS21680 in SNAP rats and saw that the pain-relieving 
effects of CGS21680 were abolished, but only for 48 hours post-anti-IL-10. This suggests that 
A2AR agonists induce sustained release of IL-10, and this contributes to the enduring effects of 
the A2aR agonist. However, we did not observe any significant changes at any timepoint in IL-10 
gene expression in the T13/L1 spinal cord following CGS21680 administration. This lack of 
significant change in IL-10 mRNA in the spinal cord is not entirely unexpected, as we have 
previously reported A2AR agonist-induced increases of IL-10 mRNA only in cells of the CSF, 
not in the actual spinal cord or meninges.
191
 We also do not observe significant changes in spinal 
IL-10 protein following A2AR agonism in SNAP (data not shown). Furthermore, we have shown 
that IL-10 protein is not up-regulated in cultured neonatal microglia or astrocytes following 
ATL313 administration.
192
 A possible reason for increased IL-10 mRNA in the CSF but not in 
the actual spinal cord or cultured glial cells after A2AR agonist administration could be that A2AR 
agonists are shifting the inflammatory phenotype of other resident and/or recruited 
immunocompetent cells to an alternative activation state.  
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In addition to neurons and glia, endothelial cells, neutrophils, and macrophages all 
express A2A receptors,
125
 and both neutrophils and macrophages are heavily influenced by their 
microenvironments and can be phenotypically shifted or polarized from one immune state to 
another.
93
 However, since neutrophils are short-lived cells
93
 and endothelial cells are classically 
thought to be more involved with trafficking and recruiting other immune cells,
125
 the most 
likely infiltrating immune cells exerting effects on spinal glia are monocytes/macrophages. At 
SCI lesion sites, microglia and resident/recruited macrophages assume a proinflammatory, or 
classical M1, phenotype.
159
 This state is characterized by increased proinflammatory mediators 
including TLR2 and 4, TNF-α, IL-1β, and IL-6.197 Additionally, M1 macrophages cause 
neurotoxicity, release oxidative metabolites, and slow axonal growth. The M1 phenotype is 
rapidly induced and can be maintained at sites of SCI for at least 1 month.
159
 Our lab has also 
demonstrated that activated meningeal immune cells can produce proinflammatory cytokines,
347
 
and that inflammatory mediators in cells of the CSF can penetrate the spinal cord and exert 
effects on glia.
297
 In contrast to the M1 cells, microglia/macrophages can take on an alternative 
(M2) activation state when the microenvironment is less proinflammatory. This phenotype is 
characterized by increased anti-inflammatory mediators including IL-10 and arginase.
197
  M2 
microglia/macrophages promote tissue healing and axonal growth following SCI. At sites of SCI, 
the M1 phenotype dominates and there are very few microglia/macrophages expressing the M2 
phenotype. However, if there is a change in the microenvironment from more proinflammatory 
to less proinflammatory, M1 microglia/macrophages can phenotypically shift to a predominately 
M2 phenotype.
159
 It has been argued that microglia/macrophages possess an M2 phenotype in the 
intact CNS.
247
 This phenomenon is also observed in IL-10 gene therapy where i.t. administration 
of plasmid IL-10 causes cells in the CSF to shift from a classically activated ED1 phenotype to a 
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more alternatively activated ED2 phenotype.
296
 In the present studies we measured arginase-1 
mRNA and protein in the spinal cord following ATL313 administration (data not shown) as a 
marker of alternative activation, but again we did not observe any significant up-regulation in 
either arginase-1 mRNA or protein, suggesting that if there is alternative activation it is likely 
coming from resident/recruited immunocompetent cells. 
The anti-inflammatory effects of adenosine agonists are not always adenosine receptor 
specific. A2AR and A2BR agonists increase cyclic adenosine monophosphate (cAMP) while A1R 
and A3R agonists decrease cAMP.
98
 A2AR agonist-induced increases of intracellular cAMP have 
been shown to reduce inflammation and apoptosis following SCI,
101
 and  A2BR agonists have 
been shown to produce similar effects on mechanical allodynia compared to A2AR agonists, 
although the reversal is not as long-lasting.
192
 In contrast, A1R and A3R agonists show very 
transient pain reversal .
44, 192
 Central administration of A1R agonists have anti-hyperalgesic 
effects in models of SCI and peripheral neuropathy, but the behavior resolves within 2 hours;
134, 
257
 not like the stable, enduring allodynic reversal defined here with A2AR agonists. Additionally, 
activation of A3Rs elicit nociceptive and proinflammatory responses in rats.
276
 Taken together, 
this supports that the anti-inflammatory effects in the present studies are specific to the A2AR and 
are not due to general adenosine activation. 
One challenge in the SCI and pain fields is identifying treatments that don’t require daily 
administration but still provide long-lasting pain relief. In the present studies, a single i.t. 
injection of an A2AR agonist reverses central neuropathic pain for up to 6 weeks. We have shown 
in SNAP that in order to achieve full reversal of allodynia using three different systemic glial 
activation inhibitors (propentofylline, ibudilast, and (+)-naltrexone), they must be administered 
daily for at least 1 week.
78
 Furthermore, once the drugs are no longer being administered the pain 
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returns. Others have shown that you need at least 3 weeks of daily dosing to fully reverse 
mechanical allodynia in both central and peripheral neuropathy .
118, 314
 Although ATL313 does 
not cross the blood brain barrier, the commercially available CGS21680 does
291
 and so could be 
administered systemically, which would allow it to be used in a larger clinical population. Thus, 
the clinical potential of these agonists is promising for long-term control of central neuropathic 
pain with very few administrations. 
Taken together, this set of studies demonstrates that a single i.t. injection of an adenosine 
A2aR agonist reverses central neuropathic pain, and that this effect is long-lasting and at least 
partially dependent on IL-10. These agonists also decrease microglial activation and the 
proinflammatory cytokine TNF-α, and are also likely up-regulating IL-10 in immunocompetent 
cells. Although more work needs to be done on elucidating the mechanisms of these agonists in 
neuropathic pain states, these agonists have the potential to be successful in treating a variety of 
chronic pain disorders.  
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Abstract 
Central neuropathic pain (CNP) is a pervasive, debilitating problem that impacts 
thousands of people living with central nervous system (CNS) disorders, including spinal cord 
injury (SCI). Unfortunately, current therapies for treating this type of pain are ineffective and 
often have intolerable side effects. Although opioids are one of the most commonly used CNP 
treatments, recent animal literature has indicated that administering opioids shortly after a 
traumatic injury can actually have deleterious effects on long-term health and recovery. This is 
important, as opioids are universally administered as a first-line intervention following a 
traumatic injury such as SCI. In addition, many SCI patients who develop chronic pain weeks or 
months after the initial injury are put on opioid regimens. In order to study the deleterious effects 
of administering morphine shortly after trauma, we used our T13 dorsal root avulsion model 
(Spinal Neuropathic Avulsion Pain, SNAP). Administering a week-long course of 10 mg/kg/day 
morphine beginning 24 hr post-SNAP amplified SNAP and gene expression of glial activation 
markers and toll-like receptor 4 (TLR4). Blocking TLR4 with the antagonist (+)-naltrexone 
prevented morphine amplification of SNAP. Furthermore, morphine also amplified IL-1β and 
NLRP3 mRNA and IL-1β protein. These data suggest that morphine can make CNP worse and 
that TLR4 and IL-1β are involved in this mechanism and could be potential treatment targets for 
preventing the deleterious effects of administering opioids after traumatic injury.   
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Introduction 
Spinal cord injury (SCI) is a debilitating condition that is the leading cause of central 
neuropathic pain, and unfortunately central neuropathic pain is usually intractable to treatment. 
Current therapies, including opioids, provide only 50% pain relief in 1 out of 2-3 patients.
92
 
Although opioids are the most effective analgesic for central neuropathic pain,
351
 recent rodent 
and clinical studies have shown that opioids administered soon after trauma can actually be 
detrimental to health and recovery.
131, 132, 270
  
In order to study central neuropathic pain in isolation from other potentially confounding 
effects of traumatic SCI, we have developed and optimized a unilateral thoracic (T) 13 and a 
unilateral T13/lumbar (L)1 avulsion (rapid rip of dorsal roots) model of SCI that does not cause 
paralysis, urinary tract infections/retention, autotomy, or other non-pain relevant aspects that can 
complicate the study of central neuropathic pain. Our model, termed SNAP (Spinal Neuropathic 
Avulsion Pain), creates physical damage to the outer laminae of the sensory dorsal horn and 
robust and reliable below-level bilateral hindpaw mechanical allodynia that lasts for ~9 weeks. 
78, 
349
 Importantly, glia (microglia and astrocytes) are activated in response to SNAP 
79
 and 
administering glial inhibitors attenuates SNAP. 
80, 81
     
Glia (microglia and astrocytes) are non-neuronal, immune-like cells of the central 
nervous system (CNS) that are normally in a quiescent/surveillance state and are responsible for 
maintaining CNS homeostasis and monitoring tissue for trauma and foreign pathogens.
311
 When 
glia become activated, they undergo numerous phenotypic and morphological changes and 
release a host of proinflammatory and neuroexcitatory mediators that include the 
proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). 
Persistent glial activation and the subsequent proinflammatory environment results in 
80 
 
neuropathic pain,
344
 including SCI-induced central neuropathic pain.
47, 137, 161
 Importantly, 
blocking glial activation in multiple classic models of SCI attenuates neuropathic pain.
111, 119
  
Glia become activated in response to their exposure to danger signals that are released by 
stressed, damaged, and dying/dead cells.
166
 It has been recently recognized that endogenous 
danger signals activate glia (especially microglia 
255
) by binding to toll-like receptor 4 (TLR4).
26
 
Importantly, we know that blocking TLR4 using the antagonist (+)-naltrexone reverses SNAP.
78
  
TLRs are pattern recognition receptors (PRRs) that are the primary sensors that recognize 
pathogen-associated molecular patterns (PAMPs), such as gram-positive and gram-negative 
bacteria.
230
 We have recently discovered that TLR4 is activated not only by alarmins, but also by 
every clinically relevant class of opioids.
141, 142, 340, 345
 This is important because virtually all SCI 
patients are treated with opioids soon after injury, whether en route to the hospital or during 
early care for acute trauma.
133
 TLR4 activation can also prime the NLRP3 inflammasome, a 
multi-protein complex involved in processing IL-1β from its pro- form to its active mature 
form.
177
 Since there are now multiple clinical
123, 270, 321, 328
 and pre-clinical
131, 132
 examples of the 
deleterious effects of opioids given shortly after trauma, and given the significant clinical 
implications this could have, the goal of these studies was to first define whether morphine 
amplifies SNAP, and if so, to determine some of the potential underlying mechanisms.  
 
Materials and Methods 
 
Animals 
Pathogen-free male Sprague-Dawley rats (325-350g; Harlan Laboratories, Madison, WI, 
USA) were used for all experiments. Rats were pair-housed prior to surgery and then single-
housed after surgery with standard rat chow and water available ad libitum. Housing was in a 
temperature-controlled room that was maintained at 23+/-2°C with a 12 hr light/dark cycle 
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(lights on at 0700 hr). The rats were allowed a minimum of 1 week to habituate to the colony 
room before initiating the experiment. All procedures were performed during the light cycle. 
Following surgery, the animals were singly housed. All protocols were approved by the 
University of Colorado at Boulder Institutional Animal Care and Use Committee.  
Drugs 
Where applicable, drugs were prepared and are reported as free base concentrations. (−)-
Morphine sulfate was gifted by Mallinckrodt, Inc. (St. Louis, MO, USA) and was dissolved in 
sterile endotoxin-free isotonic saline (Abbott Laboratories, Abbott Park, IL, USA) and 
administered at a dose of 10 mg/kg per subcutaneous (s.c.) injection. Controls received s.c. 
equivolume (1 ml/kg) saline. (+)-Naltrexone (synthesized and gifted by Kenner Rice, NIDA and 
NIAAA, Rockville, MD, USA) was dissolved in sterile endotoxin-free isotonic saline (Abbott 
Laboratories) and administered at 6 mg/kg per s.c. injection. Controls received s.c.  equivolume 
(1 ml/kg) saline. (+)-Naltrexone was given systemically as it is known to cross the blood brain 
barrier.
144
  
Spinal Neuropathic Avulsion Pain (SNAP) Surgery 
Unilateral (left) T13 dorsal root avulsion was performed under isoflurane anesthesia, as 
previously described in detail.
348
 Briefly, laminectomy was performed at the T12 vertebral level 
and the dura mater was incised over the dorsal root entry zone. The T13 dorsal rootlets were 
carefully isolated and then clamped at the dorsal root entry zone and briskly pulled out (avulsed). 
Sterile saline-moistened surgical sponge was placed over the exposed spinal cord to protect it, 
the muscle was sutured in layers with sterile 3-0 silk, and the skin was closed with stainless steel 
wound clips. Immediately following surgery, rats were single-housed in a cage with foam 
padding for a few hours to protect their spinal cord from further trauma due to the brief ataxic 
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period that follows recovery from anesthesia. Rats are placed in hanging cages immediately after 
each morphine injection with access to food and water ad libitum for ~6 hr in order to ensure 
they do not choke on bedding and to make it easier to observe their breathing and behavior.   
Sham operated rats were treated identically, except for avulsing of the rootlets. Combi-Pen-48 
antibiotic (0.2 ml; Bimeda, Inc., Le Sueur, MN, USA) was administered at the time of surgery 
and daily for 4 days after surgery. 
Low Threshold Mechanical Allodynia Testing 
 
Prior to surgery, rats were habituated to the testing environment for 4 consecutive days 
prior to recording of behavioral responses. All von Frey assessments were performed blind with 
respect to drug assignments.  Assessment of von Frey thresholds occurred before surgery 
(baseline) and across a timecourse beginning two weeks after surgery. The von Frey test was 
performed on the plantar surface of each hind paw as previously described in detail.
205
 A 
logarithmic series of 10 calibrated Semmes–Weinstein monofilaments (Stoelting) were 
sequentially applied to the left and right hind paws in random order, each for 8 s at constant 
pressure to determine the stimulus intensity threshold stiffness required to elicit a paw 
withdrawal response. Log stiffness of the hairs is determined by log10 (milligrams x10). The 
range of monofilaments used in these experiments (0.407–15.136 g) produces a logarithmically 
graded slope when interpolating a 50% response threshold of stimulus intensity (expressed as 
log10 (milligrams x10)).
41
 The stimulus intensity threshold to elicit a paw withdrawal response 
was used to calculate the 50% paw withdrawal threshold (absolute threshold) using the 
maximum-likelihood fit method to fit a Gaussian integral psychometric function.
124
 This method 
normalizes the withdrawal threshold for parametric analyses.
124
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Processing of tissue for PCR 
RNA isolation and cDNA synthesis.  Total RNA from the 5 mm piece of the T13/L1 
thoracic spinal cord was extracted using the standard phenol/chloroform extraction with TRIzol 
Reagent (Invitrogen) according to the manufacturer’s guidelines. Total RNA was reverse 
transcribed into cDNA using Superscript II First-Strand Synthesis System (Invitrogen). First-
strand cDNA was synthesized using total RNA, random hexamer primer (5 ng/µl) and 1 mM 
dNTP mix (Invitrogen) and incubated at 65°C for 5 min. After 2 min incubation on ice, a cDNA 
synthesis buffer (5 x reverse transcription (RT) buffer; Invitrogen) and dithiothreitol (10 mM) 
was added and incubated at 25°C for 2 min. Reverse transcriptase (Superscript II; 200 U; 
Invitrogen) was added to a total volume of 20 µl and incubated for 10 min at 25°C, 50 min at 
42°C, and deactivating the enzyme at 70°C for 15 min. cDNA was diluted twofold in nuclease-
free water and stored at -80°C until real-time PCR (RT-PCR) was performed. 
RT-PCR.  Primer sequences were obtained from the GenBank at the National Center for 
Biotechnology Information (www.ncbi.nlm.nih.gov) and are displayed in Table 4.1. Primers 
were generated to span an intron to eliminate genomic interference. Amplification of the cDNA 
was performed, in a blinded procedure, using Quantitect SYBR Green PCR kit (QIAGEN) in 
iCycler iQ 96-well PCR plates (Bio-Rad) on a MyiQ single Color Real-Time PCR Detection 
System (Bio-Rad). The reaction mixture (26 µl) was composed of Quanti-Tect SYBR Green 
(containing fluorescent dye SYBR Green I, 2.5 mM MgCl2, dNTP mix, and Hot Start Taq 
polymerase), 10 nM fluorescein, 500 nM each forward and reverse primer (Invitrogen), 
nuclease-free water, and 1 µl of cDNA from each sample. Each sample was measured in 
duplicate. The reactions were initiated with a hot start at 95°C for 25 min, followed by 40 cycles 
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of 15 s at 94°C (denaturation), 30 s at 55–60°C (annealing), and 30 s at 72°C (extension). Melt 
curve analyses were conducted to assess uniformity of product formation, primer–dimer 
formation, and amplification of nonspecific products. The PCR product was monitored in real-
time, using the SYBR Green I fluorescence, using the MyiQ Single-Color Real-Time PCR 
Detection System (Bio-Rad). Threshold for detection of PCR product was set in the log-linear 
phase of amplification and the threshold cycle (CT) was determined for each reaction. The level 
of the target mRNA was quantified relative to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) using the comparative CT (ΔCT) method. The expression of 
GAPDH was not significantly different between treatments. 
Table  4.1. Primer Sequences  
Gene   Primer Sequence (5′-3′)    GenBank accession no. 
GAPDH (i-s)  TCTTCCAGGAGCGAGATCGC (forward)   NG_028301.1 
                          TTCAGGTGAGCCCCAGCCTT (reverse) 
 
 CD11b (i-s)  CTGGTACATCGAGACTTCTC (forward)  NM_012711.1 
TTGGTCTCTGTCTGAGCCTT (reverse)  
___________________________________________________________________________________________ 
GFAP (i-s)  AGATCCGAGAAACCAGCCTG (forward)   NM_017009.2 
CCTTAATGACCTCGCCATCC (reverse) 
 
TLR4 (i-s)  TCCCTGCATAGAGGTACTTC (forward)   NM_019178.1 
CACACCTGGATAAATCCAGC (reverse) 
 
TNF-α (i-s)  CAAGGAGGAGAAGTTCCCA (forward)   NM_012675.3 
 TTGGTGGTTTGCTACGACG (reverse) 
 
IL-1β (i-s)  CCTTGTGCAAGTGTCTGAAG (forward)   NM_031512.2 
 GGGCTTGGAAGCAATCCTTA (reverse) 
 
NLRP3 (i-s)  AGAAGCTCCCCTTGGTGAATT (forward)   NM_001191642.1 
GTTGTCTAACTCCAGCATCTG (reverse) 
  
i-s, intron-spanning primers generated to reduce genomic interference 
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Enzyme linked immunosorbant assay (ELISA) 
IL-1β protein in rat T13/L1 ipsilateral dorsal spinal cord was analyzed using a 
commercially available ELISA kit specific for rat IL-1 (R&D Systems, Minneapolis, MN, USA). 
The sensitivity of the IL-1β assay is less than 5 pg/mL. 
Western Blot 
Thoracic T13/L1 ipsilateral dorsal spinal cord (~5 mm piece) was sonicated in a cocktail 
containing extraction buffer (Invitrogen, Carlsbad, CA, USA) and protease inhibitors (Sigma, St. 
Louis, MO, USA). Ice-cold tissue samples were centrifuged at 14,000 rpm at 4°C for 10 min. 
The resulting supernatant was removed and the protein concentration of each sample was 
quantified using the Bradford method. Protein samples were loaded into a standard 
polyacrylamide gel (8-12% 15 well Bis-Tris Gel, Invitrogen). Electrophoresis was performed in 
MOPS running buffer using the XCell SureLock Mini-Cell (Invitrogen). Protein was transferred 
onto a nitrocellulose membrane using the iBlot system (Bio-Rad, Hercules, CA, USA). The 
membrane was blocked with Odyssey blocking buffer (Li-COR Biosciences, Lincoln, NE, USA) 
for 1 hr and incubated with NLRP3 primary antibody (LifeSpan BioSciences, Seattle, WA, USA)  
in blocking buffer at a dilution of 1:500 and β-actin (Sigma) at a dilution of 1:1,000 overnight at 
4 °C. The following day, the membrane was washed and then incubated in goat-anti-rabbit for 
NLRP3 and goat-anti-mouse for β-actin secondary antibody both at a dilution of 1:10,000 at RT 
for 1 hr. Protein expression was visualized and quantified using the Odyssey Infrared Imager (Li-
COR Biosciences).  
Pharmacological Manipulations 
 
Effect of administering a week-long course of morphine beginning 24 hr post-surgery 
on SNAP 
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Morphine (10 mg/kg) or equivolume vehicle (saline) was administered once daily for 7 
days beginning 24 hr post-SNAP (n = 6 per group). Sham rats are not the most appropriate 
controls because the traumatic nature of the sham surgery can also be potentiated by morphine. 
Instead, a group of surgically naïve rats were given the same course of morphine as the SNAP 
rats and placed in the hanging cages at the same time as the SNAP rats for 7 days. Rats were then 
given 1 week to fully recover from surgery and completely clear out the morphine. At 2 weeks 
post-surgery, rats were behaviorally tested to define their mechanical response thresholds once a 
week for 5 weeks post-surgery.   
Effect of administering a week-long course of morphine beginning 24 hr post-surgery 
on glial activation marker, TLR4, and TNF-α gene expression 
 After recording behavioral responses at the 1 week or 5 week post-drug treatment 
timepoint, SNAP rats that received morphine (10 mg/kg s.c.) or vehicle and two groups of 
surgically naïve rats, one that received no manipulation and was kept in their home cage and one 
that received the same course of morphine as the SNAP rats (10 mg/kg s.c. once a day for 7 
days; all groups n = 6-8 per group) and placed in the hanging cages, were overdosed with sodium 
pentobarbital (0.8 ml) and transcardially perfused with ice-cold 0.9% saline for 2 min. The spinal 
cord was dissected and a 5 mm piece of ipsilateral dorsal spinal cord, with the meninges 
removed, was dissected out to include the T13/L1 spinal level. All tissue was flash frozen in 
liquid nitrogen. Samples were then stored at -80°C until analysis.  
Effect of co-administering a week-long course of morphine and the TLR4 antagonist 
(+)-naltrexone beginning 24 hr post-surgery on SNAP  
(+)-Naltrexone (6 mg/kg s.c.) or equivolume vehicle (Saline) was administered three 
times a day at approximately 0900, 1200, and 1500 hr for 7 days beginning 24 hr post-surgery. 
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Immediately after the first (+)-naltrexone injection each day, morphine was injected once a day 
for 7 days at 10 mg/kg s.c. beginning 24 hr post-surgery. Beginning 2 weeks post- surgery, rats 
were behaviorally tested to define their mechanical response thresholds once a week for 10 
weeks post-surgery. 
Effect of administering a week-long course of morphine 24 hr post-surgery on IL-1β 
and NLRP3 inflammasome marker protein and gene expression 
After recording behavioral responses at the 1 week post-drug treatment (2 weeks post-
SNAP) timepoint, SNAP rats that received morphine (10 mg/kg s.c.) or vehicle and a group of 
surgically and drug naïve rats (n = 6 per group, each condition repeated twice to obtain tissues 
for protein and mRNA), were overdosed with sodium pentobarbital (0.8 ml) and transcardially 
perfused with ice-cold 0.9% saline for 2 min. The spinal cord was dissected and a 5 mm piece of 
ipsilateral dorsal spinal cord, with the meninges removed, was dissected out to include the 
T13/L1 spinal level. All tissue was flash frozen in liquid nitrogen. Samples were then stored at -
80°C until analysis. 
Statistical Analysis 
All data were analyzed using GraphPad Prism version 5.04 for Windows Vista 
(GraphPad Software, San Diego, CA, USA). Ipsilateral and contralateral behavioral data were 
analyzed individually. Behavioral measures were normalized as described above and group 
differences were analyzed by comparing area under the curve (AUC), as previously described by 
Jones and Sorkin.
152
 AUC values (GraphPad Prism 5.01; GraphPad software Inc., San Diego, 
CA) were calculated from absolute threshold values, from 3.56 (the lowest threshold response 
value in the data set) up to the threshold response of each rat across time. Then a one-way 
ANOVA was performed on the AUC values for each group. Decreased AUC reflects an increase 
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in mechanical allodynia. For all studies, the AUC measures across time were collapsed into a 
single timepoint for each animal, thus there is not a repeated measurement. For baseline 
measurements, a one-way ANOVA at that single timepoint was the statistic used. The RT-PCR, 
western blot, and ELISA data were analyzed using a one-way ANOVA. Bonferroni post hoc 
tests were used where appropriate, and p < 0.05 was considered statistically significant. 
Results 
Effect of administering a week-long course of morphine beginning 24 hr post-surgery 
 
 on SNAP 
 
In order to determine if morphine amplifies SNAP, morphine (10 mg/kg s.c.) or vehicle 
was administered once a day for one week beginning 24 hr post-surgery. No differences were 
observed between groups in the response thresholds recorded for the hindpaw ipsilateral (Fig 
4.1A) or contralateral (Fig 4.1B) to the avulsion injury pre-surgery [baseline (BL)]. The one-way 
ANOVA comparing the AUC of Naive+Morphine, SNAP+Vehicle, and SNAP+Morphine from 
2-5 weeks post-surgery was significant in both the ipsilateral (F2,15 = 31.21; p<0.0001; Fig 4.1C) 
and contralateral (F2,15 = 25.15; p<0.001; Fig 4.1D) hindpaw. Bonferroni post hoc analysis of the 
AUCs revealed that the SNAP+Morphine group was significantly more allodynic than all other 
groups (p<0.05) in both the ipsilateral and contralateral hindpaw. Furthermore, the 
SNAP+Vehicle group was significantly more allodynic than the Naïve+Morphine group in both 
the ipsilateral and contralateral hindpaw (p<0.05).  
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Figure 4.1: Effect of administering a week-long course of morphine beginning 24 hr post- 
surgery on SNAP 
 
Figure 4.1. Assessment of the effects of morphine on SNAP. Rats were tested for mechanical 
allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) hindpaw. SNAP 
rats that received morphine (10 mg/kg, s.c.) for 7 days beginning 24 hours after surgery were 
significantly more allodynic than SNAP rats that received vehicle and naïve rats that received 
morphine in both the ipsilateral (C) and contralateral (D) hindpaw. Data are presented as mean ± 
SEM and analyzed using a one-way ANOVA on the AUCs, n=6 per group. *p<0.05 compared to 
all other groups, 
+
p<0.05 compared to Naïve+Morphine group. 
 
Effect of administering a week-long course of morphine beginning 24 hr post-surgery 
on glial activation marker, TLR4, and TNF-α gene expression 
Since morphine amplified SNAP, we also wanted to determine if morphine amplified 
mRNA expression of the glial activation markers CD11b and GFAP as well as TLR4 and TNF-
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α. The one-way ANOVA for CD11b mRNA was significant at both the 1 week (F3,21 = 27.32; 
p<0.0001; Fig 4.2A) and 4 weeks (F3,19 = 25.02; p<0.0001; Fig. 4.2B) timepoint post-final 
morphine injection. Bonferroni post hoc analysis revealed that CD11b mRNA was significantly 
increased in the SNAP+Vehicle group (p<0.05) at both timepoints compared to both naïve 
groups, and was further amplified by morphine at both timepoints. There was no significant 
difference between the naïve groups at either timepoint. The one-way ANOVA for GFAP 
mRNA was also significant at both the 1 week (F3,15 = 23.91; p<0.0001; Fig. 4.2C) and 4 week 
(F3,15 = 9.905; p<0.001; Fig. 4.2D) timepoint post-final morphine injection. Bonferroni post hoc 
analysis revealed that GFAP mRNA was significantly increased in the SNAP+Vehicle group 
(p<0.05) compared to both naïve groups, and was further amplified by morphine only at the 1 
week post-final morphine injection timepoint. At the 4 week post-final morphine injection 
timepoint, the SNAP+Morphine group was only different from the two naïve groups and there 
were no other differences between any groups. There was no significant difference between the 
naïve groups at either timepoint. The one-way ANOVA for TLR4 mRNA was significant at both 
the 1 week (F3,20 = 18.67; p<0.0001; Fig. 4.3A) and 4 week (F3,21 = 3.469; p<0.05; Fig. 4.3B) 
timepoint post-final morphine injection. Bonferroni post hoc analysis revealed that TLR4 mRNA 
was significantly increased in the SNAP+Vehicle group (p<0.05) compared to both naïve 
groups, and was further amplified by morphine only at the 1 week post-final morphine injection 
timepoint. There were no significant differences between groups at the 4 weeks post-final 
morphine injection timepoint. There was no significant difference between the naïve groups at 
either timepoint. The one-way ANOVA for TNF-α mRNA was significant at both the 1 week 
(F3,22 = 4.736; p<0.05; Fig. 4.3C) and 4 week (F3,20 = 7.241; p<0.01; Fig. 4.3D) timepoint post-
final morphine injection. Bonferroni post hoc analysis revealed that at the 1 week post-final 
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morphine injection timepoint, TNF-α was significantly increased only in the SNAP+Morphine 
group (p<0.05), although there was a strong trend for a significant increase in the SNAP+Vehicle 
group. At the 4 week post-final morphine injection timepoint, the SNAP+Vehicle group and the 
SNAP+Morphine group were not significantly different from each other, but were both 
significantly different from both naïve groups (p<0.05). There was no significant difference 
between the naïve groups at either timepoint. 
Figure 4.2: Effect of administering a week-long course of morphine beginning 24 hr post-
surgery on glial activation marker mRNA gene expression 
 
Figure 4.2. Assessment of the effects of administering morphine on CD11b and GFAP mRNA 
gene expression in the T13/L1 ipsilateral dorsal spinal cord. SNAP significantly increased 
CD11b mRNA at both the 1 week (A) and 4 week (B) timepoint post-last injection, and 
morphine furthered amplified CD11b at both timepoints. SNAP significantly increased GFAP 
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mRNA at both the 1 week (C) and 4 week (D) timepoint post-final morphine injection, and 
morphine further amplified GFAP only at the 1 week timepoint. Data are presented as mean ± 
SEM and analyzed using a one-way ANOVA, n= 5 to 7 per group. *p<0.05 compared to all 
other groups, 
+
p<0.05 compared to both naïve groups.   
 
Figure 4.3: Effect of administering a week-long course of morphine beginning 24 hr post-
surgery on TLR4 and TNF-α mRNA gene expression 
 
Figure 4.3. Assessment of the effects of administering morphine on TLR4 and TNF-α mRNA 
gene expression in the T13/L1 ipsilateral dorsal spinal cord. SNAP significantly increased TLR4 
mRNA at both the 1 week (A) and 4 week (B) timepoint post-final morphine injection, but 
morphine only amplified TLR4 mRNA at the 1 week timepoint. Only morphine significantly 
increased TNF-α mRNA at the 1 week (C) timepoint post-final morphine injection, while both 
SNAP and morphine increased TNF-α mRNA at the 4 week (D) timepoint post-final morphine 
injection. Morphine did not further amplify TNF-α mRNA at the 4 week timepoint. Data are 
presented as mean ± SEM and analyzed using a one-way ANOVA, n= 5 to 7 per group. *p<0.05 
compared to all other groups, 
+
p<0.05 compared to both naïve groups.   
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Effect of co-administering a week-long course of morphine and the TLR4 antagonist 
(+)-naltrexone beginning 24 hr post-surgery on SNAP 
In order to determine if antagonizing TLR4 blocks morphine amplification of SNAP, the 
TLR4 antagonist (+)-naltrexone (6 mg/kg/inj s.c.) or vehicle was co-administered with morphine 
(single 10 mg/kg s.c. injection per day) or vehicle once a day and then administered alone two 
more times a day for one week beginning 24 hours post-surgery. All rats received SNAP surgery. 
No differences were observed between groups in the response thresholds recorded for the 
hindpaw ipsilateral (Fig 4.4A) or contralateral (Fig 4.4B) to the avulsion injury pre-surgery 
[baseline (BL)]. The one-way ANOVA comparing the AUC of Vehicle+Vehicle, 
Morphine+Vehicle, and Morphine+(+)-Naltrexone from 2-10 weeks post-surgery was significant 
in both the ipsilateral (F2,15 = 9.892; p<0.01; Fig 4.4C) and contralateral (F2,13 = 6.679; p<0.05; 
Fig 4.4D) hindpaw. Bonferroni post hoc analysis of the AUCs revealed that the 
Morphine+Vehicle group was significantly more allodynic than all other groups (p<0.05) in both 
the ipsilateral and contralateral hindpaw. Furthermore, there were no significant differences 
between the other two groups in both the ipsilateral and contralateral hindpaw (p<0.05). 
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Figure 4.4: Effect of co-administering a week-long course of morphine and the TLR4 
antagonist (+)-naltrexone beginning 24 hr post-surgery on SNAP 
 
 
Figure 4.4. Assessment of the effects of morphine + (+)-naltrexone on SNAP. Rats were tested 
for mechanical allodynia across a timecourse on both the ipsilateral (A) and contralateral (B) 
hindpaw. SNAP rats that received (+)-naltrexone (3x 6 mg/kg, s.c.) + morphine (10 mg/kg, s.c.) 
for 7 days beginning 24 hours after surgery were significantly less allodynic than SNAP rats that 
received morphine + saline and were not significantly different than SNAP rats that received 
vehicle + vehicle in both the ipsilateral (C) and contralateral (D) hindpaw. Data are presented as 
mean ± SEM and analyzed using a one-way ANOVA on the AUCs, n=6 per group. *p<0.05 
compared to all other groups. 
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Effect of administering a week-long course of morphine 24 hr post-surgery on IL-1β 
and NLRP3 inflammasome marker protein and gene expression 
Next we wanted to look at markers of the NLRP3 inflammasome and define if morphine 
amplified mRNA and protein at a single timepoint. Since the naïve+morphine group in the above 
studies were not statistically different from the naïve group for any marker analyzed, only a 
naïve group will be presented here. The one-way ANOVA for IL-1β mRNA was significant 
(F2,16 = 10.03; p<0.01; Fig 4.5A) and was also significant for IL-1β protein (F2,15 = 14.54; 
p<0.001; Fig. 4.5B). Bonferroni post hoc analysis revealed that IL-1β mRNA and protein was 
significantly increased in the SNAP+Vehicle group (p<0.05) compared to the naïve group, and 
was further increased by morphine. The one-way ANOVA for NLRP3 mRNA was significant 
(F2,16 = 10.59; p<0.01; Fig 4.5C) and was also significant for NLRP3 protein (F2,20 = 33.3; 
p<0.0001; Fig 4.5D). Bonferroni post hoc analysis revealed that NLRP3 mRNA was 
significantly increased in the SNAP+Vehicle group (p<0.05) compared to the naïve group, and 
was further increased by morphine, and that NLRP3 mRNA was significantly increased in the 
SNAP+Vehicle group (p<0.05) compared to the naïve group, but was not further amplified by 
morphine. 
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Figure 4.5: Effect of administering a week-long course of morphine 24 hr post-surgery on 
IL-1β and NLRP3 inflammasome mRNA gene expression and protein 
 
Figure 4.5. Assessment of the effects of administering morphine on IL-1β and NLRP3 mRNA 
gene expression and protein in the T13/L1 dorsal spinal cord. SNAP significantly increased IL-
1β mRNA (A) and protein (B) which were both further amplified by morphine. SNAP 
significantly increased NLRP3 mRNA (C) and protein (D), but only the mRNA was further 
amplified by morphine. Data are presented as mean ± SEM and analyzed using a one-way 
ANOVA, n= 6-8 per group. *p<0.05 compared to all groups, 
+
p<0.05 compared to the naïve 
group.   
 
 
 
 
97 
 
Discussion 
 Although opioids have long been one of the most effective analgesics used for 
pain, it is important to recognize that there may also be detrimental effects of administering 
opioids for pain in certain situations. In the present set of studies, we provide evidence that a 
week-long course of morphine starting 24 hours after avulsion SCI amplifies central neuropathic 
pain for 4 weeks. This amplification of central neuropathic pain was blocked by administering 
the TLR4 antagonist (+)-naltrexone. Morphine also amplified SNAP-induced mRNA gene 
expression of markers of glial activation at both 1 and 4 weeks after the final morphine injection, 
and TLR4 mRNA 1 but not 4 weeks after the last morphine administration. Lastly, morphine 
amplified both SNAP-induced mRNA and protein expression of IL-1β and amplified SNAP-
induced mRNA but not protein expression of the NLRP3 inflammasome. It is important to note 
that all of these changes were observed in tissue collected 1 week after the final morphine dose, 
and thus cannot be attributed to active morphine metabolism. Furthermore, we know that 
morphine administration in naive rats does not induce pain and inflammation; there must already 
be a proinflammatory environment in order to observe morphine-potentiated effects. 
We are not the first to describe deleterious effects of administering opioids shortly after 
trauma. Hook et al. reported that a single injection of intrathecal morphine 24 hours following 
contusion SCI attenuated weight gain and locomotor function and increased tissue loss around 
the SCI lesion site.
132
 Interestingly, they did not find any differences in mechanical reactivity at 
day 21 post-surgery, although this is not surprising because it was a single injection of intrathecal 
morphine rather than a more clinically relevant multi-day course of administration. We are thus 
the first group to show that chronic opioid administration shortly after surgery/traumatic injury 
amplifies central neuropathic pain for weeks after the initial injury. Hook et al. also suggest that 
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glia are involved in the mechanism by which morphine undermines health and recovery,
133
 and 
our data in the present studies demonstrate that glia are playing a key role in morphine 
amplification of central neuropathic pain. 
We have established that morphine binds to the non-classic opioid receptor TLR4, 
inducing glial activation and the release of proinflammatory cytokines.
140, 143, 145, 345
 Glia are 
activated in multiple models of SCI,
38, 46, 350
 and here we show that spinal mRNA of the 
microglial activation marker CD11b and astrocyte activation marker GFAP are increased in 
SNAP 2 weeks post-surgery and remain elevated 5 weeks post-surgery. Furthermore, morphine 
amplifies both of these markers at both timepoints, indicating that morphine is likely acting on 
glial cells and amplifying their activation via TLR4. In addition, it is known that TLR4 mRNA 
levels are increased by 72 hr in contusion injury,
160
 and here TLR4 mRNA is still increased by 
SNAP 2 weeks post-surgery and is further increased by morphine. TNF-α is increased in the 
spinal cord after hemisection SCI,
238
 and TNF-α blockade decreases inflammation and improves 
motor recovery in an experimental mouse model of SCI.
100
 Morphine increased TNF-α mRNA 2 
weeks post-surgery, but surprisingly SNAP alone did not increase TNF-α (we believe that if we 
had the appropriate control group to allow us to run a 2-way ANOVA, SNAP+Vehicle would 
significantly increase TNF-α mRNA at this timepoint). However, TNF-α mRNA was 
significantly increased in the SNAP+Vehicle and SNAP+Morphine groups compared to the 
naïve groups at the later timepoint (although there is not a morphine-potentiated increase of 
TNF-α at this timepoint).  TLR4 mRNA is no longer increased by SNAP or potentiated by 
morphine 5 weeks post-surgery, but both microglia and astrocyte activation markers (CD11b and 
GFAP, respectively) are. This suggests that both microglia and astrocytes are involved in both 
the initiation and the long-term maintenance of morphine amplification of SNAP.    
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Previous studies from our lab have shown that both peripheral and central neuropathic 
pain can be reversed by the TLR4 antagonist (+)-naltrexone.
78, 144
 Here, (+)-naltrexone was able 
to block morphine amplification of SNAP, which is more evidence that TLR4 is critically 
involved in the mechanism underlying morphine amplification of SNAP. Of note, the group of 
rats that received morphine plus (+)-naltrexone was trending toward being significantly less 
allodynic than the vehicle plus vehicle group even after 5 weeks post-surgery when morphine is 
no longer potentiating SNAP. We realize that opioids are often the least expensive and most 
effective treatment available for chronic pain, and are not advocating that opioids should be 
completely banned from clinical use. What is promising about the (+)-naltrexone data is that (+)-
naltrexone could be co-administered with opioids in order to allow classical mu opioid binding 
for analgesia while blocking opioid binding at TLR4 and preventing glial activation and 
subsequent amplification of neuropathic pain and inflammation. Notably, based on prior studies 
of (+)-naltrexone and acute morphine, blocking TLR4 in this manner potentiates acute morphine 
analgesia, implying that (+)-naltrexone would provide improved morphine analgesia at the same 
time as preventing the long-term deleterious effects on chronic pain. 
The proinflammatory cytokine IL-1β  is key to the inflammatory cascade and is therefore 
very tightly regulated.
68
 IL-1β mRNA and protein are up-regulated in SCI,237, 244, 337 and Hook et 
al. blocked morphine-induced attenuation of locomotor recovery by administering IL-1 receptor 
antagonist.
133
 Both IL-1β mRNA and protein are increased by SNAP 2 weeks post-surgery, and 
are both further amplified by morphine. These data demonstrate that IL-1β is an important 
cytokine involved in morphine amplification of SNAP, and could provide a future therapeutic 
target. The way in which IL-1β  is processed is different than most other cytokines; it must be 
cleaved from a precursor protein (pro-IL-1β) into a mature protein that can then be released.327 
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The molecule that cleaves the pro-form of IL-1β into the mature form is the protease caspase-1, 
which must also be cleaved from a precursor protein, pro-caspase-1.
174
 Pro-caspase-1 is cleaved 
through the formation and activation of a group of intracellular proteins collectively called the 
inflammasome.
213
 There are 6 NLR inflammasomes (NLRP1, 2, 3, 6, 7, and NLRC4), and 3 of 
these (NLRP1, 2, 3) have been identified in the CNS.
121, 200, 209
 NLRP3 is the only one known to 
be expressed on microglia.
121
 The NLRP3 inflammasome is unique in that basal NLRP3 protein 
expression is too low for actual formation/activation of the inflammasome. 
14
 In order for 
NLRP3 inflammasome formation to occur, the NLRP3 gene must first be transcribed and 
translated into protein. This step is thought to require TLR4 ligation, and is called the “priming” 
step. After enough NLRP3 protein has accumulated, a second signal is required for NLRP3 to 
become active, which results in the cleavage/activation of pro-caspase-1 which then cleaves pro- 
IL-1β into its mature protein form. In the present studies, there is a significant increase in NLRP3 
mRNA induced by SNAP and amplified by morphine but no significant increase in NLRP3 
protein. This is indicative of NLRP3 priming, but since there does not appear to be significant 
morphine-induced amplification of NLRP3 inflammasome activation, this cannot fully explain 
the increase and further morphine-induced amplification of IL-1β protein. One possibility is that 
since the IL-1β mRNA and protein is measured from spinal cord tissue homogenates, we cannot 
be sure that the IL-1β is mature IL-1β and not pro- IL-1β. There is also evidence that NLRP1 is 
involved in the inflammatory response in SCI
61
 and traumatic brain injury.
63
 In addition, there 
are other inflammasome-independent mechanisms of IL-1β processing that could be occurring 
and contributing to the inflammatory response, such as through activation of caspases-11 and/or 
8.
177
 Lastly, other proinflammatory mediators, such as TNF-α, could be playing a role in this 
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mechanism as well, since we know that TNF-α mRNA is up-regulated by SNAP and amplified 
by morphine. 
The analgesic properties of opioids have been thoroughly studied for many years, but 
only recently have there been reports in the clinical literature of the deleterious effects of 
administering opioids. In one study, Salengros et al. found that a higher dose of the opioid 
remifentanil resulted in worse post-operative pain in patients compared to a lower dose,
270
 which 
suggests that some of these detrimental effects could be dose-dependent. In addition, patients 
who received the higher dose of remifentanil had a larger area of allodynia around the operation 
site 1 month after the surgery, which is mirrored in the current rat studies demonstrating 
morphine amplification of pain 5 weeks post-surgery. In other studies, van Gulik et al. found that 
remifentanil administration during cardiac surgery dose-dependently predicted chronic thoracic 
pain in patients 1 yr later,
328
 and Hansen et al. found that patients given remifentanil during 
abdominal surgery had worse post-operative pain compared to those who did not receive 
remifentanil.
123
 Furthermore, trauma patients who were on a chronic opioid regimen had 
significantly higher pain 4 months after the original injury compared to those who never received 
opioids.
321
  Taken together, all of the animal and clinical literature suggests that it is important to 
understand the mechanisms underlying the deleterious effects of administering opioids in order 
to develop new treatments and/or to improve the efficacy of current treatments.   
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Chapter V 
 General Discussion 
 Summary of main experimental results 
 Central neuropathic pain is a pervasive problem, especially in spinal cord injury (SCI), 
and is unfortunately often intractable to treatment. It is now well known that in addition to 
neurons, glial cells are responsible for initiating and maintaining neuropathic pain states,
344
 and 
that by blocking glial activation, neuropathic pain can be prevented,
309
 attenuated,
111
 and 
reversed.
78
 However, the underlying mechanisms involved are still only partially understood. 
The goal of this dissertation was to characterize and elucidate some of these mechanisms in order 
to better understand central neuropathic pain and to help guide the development of better chronic 
pain treatments. 
 In chapter II, a series of studies was conducted in order to determine if our T13/L1 dorsal 
root avulsion model of SCI, SNAP, could be reversed by three different glial activation 
inhibitors, each with a distinct mechanism of action. In the first set of experiments, the 
phosphodiesterase (PDE) inhibitor propentofylline (PPF) was administered once daily 
intraperitonially (i.p.) at 10 mg/kg for two weeks beginning four weeks post-surgery, and 
responses to a mechanical stimulus were recorded weekly in the first experiment. In the next 
experiment, responses were recorded every two to four days in order to provide a more detailed 
timecourse as to how quickly PPF reversed SNAP-induced allodynia. PPF reversed SNAP-
induced allodynia in both the ipsilateral and contralateral hindpaws, and the complete reversal 
took about one week. These results suggested that glia were involved in SNAP and that PDE 
inhibition could be important in glial mechanisms for treating neuropathic pain. PDE activation 
has also been implicated in depression and anxiety,
242
 stroke,
127
 MS,
69
 multiple models of 
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neuropathic pain,
215, 355, 356
 Huntington’s disease,104 schizophrenia,294 arterial hypertension,60 
renal disease,
45
 and asthma/chronic obstructive pulmonary disease (COPD);
87
 and inhibiting 
PDEs in these diseases is usually beneficial. We next wanted to explore whether or not a glial 
activation inhibitor that inhibited PDE but also had a well defined different mechanism of action 
would also attenuate SNAP. In addition, we wanted to know if we could reverse SNAP both 
early and late in the development of allodynia. Ibudilast is known to have PDE inhibitory action 
as well as macrophage migration inhibitory factor (MIF) inhibitory action.
179, 264
 Ibudilast was 
administered subcutaneously (s.c.) once daily at 10 mg/kg for five weeks beginning four weeks 
post-surgery (late in the development of SNAP) and for three weeks beginning two week post-
surgery (early in the development of SNAP). In both studies ibudilast reversed SNAP in both the 
ipsilateral and contralateral hindpaws. These data indicated that PDE inhibition alone could not 
account for the anti-inflammatory effects of ibudilast and that in addition to PDE inhibition, MIF 
inhibition could also be important for glial mechanisms underlying chronic pain. MIF has been 
implicated in COPD,
86
 asthma,
313
 stroke,
338
 MS,
116
 TBI,
323
 and SCI,
226
 and ibudilast has been 
used to treat asthma,
155
 COPD,
10
 stroke,
180
 TBI,
262
 SNL pain,
179
 CCI pain,
119
 and SCI pain,
78
 and 
has been studied in clinical trials for MS.
264
  Lastly, we wanted to determine if a glial activation 
inhibitor that had no known PDE or MIF activity could reverse SNAP. The selective TLR4 
antagonist (+)-naltrexone was administered s.c. three times daily at 6 mg/kg/inj for two weeks 
beginning approx. four weeks post-surgery, and (+)-naltrexone reversed SNAP in both the 
ipsilateral and contralateral hindpaws. Furthermore, when (+)-naltrexone was given for five days 
and then stopped, the allodynia gradually returned over approximately one week. This suggests 
that (+)-naltrexone decreased proinflammatory signaling in glia and/or neurons and was able to 
maintain pain relief for a short time after drug clearance, but was not able to induce permanent 
104 
 
changes that could overcome the proinflammatory environment and persistent glial activation 
caused by the original SCI.  
 These studies indicated that the pain reversal by (+)-naltrexone was glially mediated via 
antagonism of TLR4 since TLR4 is found predominately on glial cells in the CNS.
141
 Since 
TLR4 activation can result in downstream proinflammatory cytokine and MIF release,
106, 253
 it is 
likely that glial activation via TLR4 is mechanistically important in SNAP and administration of 
PDE, MIF, and TLR4 inhibitors are acting either directly or indirectly on glial signaling via 
TLR4, resulting in decreased allodynia. Taken altogether, the studies in chapter II provide strong 
evidence for an important role of glia in the mechanisms underlying SNAP via PDE, MIF, and 
TLR4 actions. However, there are also other mechanisms and receptors to target for glially-
mediated pain control. 
 Adenosine A2A receptors have recently garnered much attention in the literature for anti-
inflammatory effects exerted upon their activation in peripheral immune cells.
125, 306
 Such a 
profile is suggestive that they have the potential to be effective glial inhibitors as well. Chapter 
III details a set of studies aimed at exploring the effects of administering adenosine A2A receptor 
agonists in SNAP. A single intrathecal (i.t.) injection of 10 µM CGS21680 administered four 
weeks post-surgery reversed SNAP in both the ipsilateral and contralateral hindpaws for at least 
six weeks. If a single i.t. injection of neutralizing IL-10 antibody (0.2 µg/ml in 10 µL) was given 
one week post-CGS21680 (10 µM), the anti-allodynic effect of CGS21680 was completely 
abolished for approximately forty-eight hours. This indicated that the anti-inflammatory cytokine 
IL-10 is important in the mechanism by which CGS21680 exerts its anti-allodynic effect. 
Furthermore, since the effect of neutralizing IL-10 only lasted approximately forty-eight hours, it 
seems as though CGS21680 induced a long-term alteration in cells releasing IL-10. Ipsilateral 
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T13/L1 dorsal spinal cord tissue collected one and six weeks post-CGS21680 was then analyzed 
for mRNA gene expression of IL-10, the microglial activation marker CD11b, and the 
proinflammatory cytokine TNF-α. CGS21680 decreased CD11b and TNF-α at both timepoints, 
but there were no differences in gene expression of IL-10 at either timepoint. These data 
suggested that CGS21680 attenuated inflammation in part by decreasing microglial activation 
and the subsequent release of TNF-α. Since there were no differences in IL-10 mRNA, this could 
indicate that the source of IL-10 is from infiltrating immune cells in the CSF as suggested in 
prior publications.
191, 192
 The last set of studies was undertaken in order to determine if adenosine 
A2AR agonists would be able to prevent SNAP and reverse well-established SNAP. We also 
wanted to use a different agonist to provide converging lines of evidence that the effects were 
indeed a result of A2AR activation, rather than being agonist-specific. A single i.t. injection of 1 
µM ATL313 administered one week post-surgery attenuated the development of SNAP in both 
the ipsilateral and contralateral hindpaws. ATL313 also reversed established SNAP when 
administered seven weeks post-surgery in both the ipsilateral and contralateral hindpaws. These 
last studies confirmed that the anti-allodynic effect was not agonist specific and that they could 
be administered at a variety of timepoints with similar success. Overall, chapter III demonstrated 
that A2AR agonists are promising glial inhibitors for treating central neuropathic pain. In contrast, 
one of the most commonly used therapeutics for pain, opioids, which activate glia, may actually 
be detrimental to health and recovery.  
 Opioids are normally thought of as being excellent analgesics and helpful rather than 
harmful for controlling pain. However, the studies in chapter IV demonstrate a case where pain 
and inflammation can actually be amplified by administering a course of morphine shortly after 
injury. In the first set of experiments, a week-long course of morphine (10 mg/kg s.c.) 
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administered beginning twenty-four hours post-surgery amplified SNAP for four weeks. 
Importantly, this same course of morphine given to naïve rats did not produce amplification of 
pain, indicating that trauma/inflammation is necessary in order to observe this potentiated pain 
and would not occur in a normal healthy individual. Ipsilateral T13/L1 dorsal spinal tissue 
collected one and four weeks after the final morphine administration was analyzed for mRNA 
gene expression of CD11b, the astrocyte activation marker GFAP, toll-like receptor 4 (TLR4), 
and the proinflammatory cytokine TNF-α. CD11b and GFAP mRNA were increased by SNAP 
alone and were further amplified by morphine at both the one and four week timepoint, and 
TLR4 mRNA was increased by SNAP alone and further amplified by morphine only at the one 
week timepoint. TNF-α mRNA was amplified by morphine at the one week timepoint and was 
increased by SNAP and morphine compared to naïve controls at the four week timepoint, but 
was no longer amplified by morphine. These data suggested that morphine could be potentiating 
pain by amplifying glial activation and the subsequent release of proinflammatory mediators. 
Since TL4 mRNA was amplified by morphine and also because we have previously shown that 
(+)-naltrexone reverses SNAP,
78
 we hypothesized that TLR4 could be involved in the 
mechanism of morphine amplification of SNAP and that antagonizing TLR4 would block this 
amplification. In order to test this hypothesis, (+)-naltrexone (three times daily 6 mg/kg/inj s.c.) 
was administered with our typical course of morphine (once daily 10 mg/kg s.c. for seven days 
beginning twenty-four hours post-surgery). As expected, (+)-naltrexone blocked morphine 
amplification of SNAP in both the ipsilateral and contralateral hindpaws, suggesting that 
morphine is potentiating TLR4 activation on glial cells, thereby amplifying pain. The final study 
was designed to determine the possible mechanisms of morphine amplification of 
neuroinflammation. Spinal tissue collected one week after the last morphine dose was analyzed 
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for mRNA gene expression and protein expression of the proinflammatory cytokine IL-1β and 
the NLRP3 inflammasome, which is partially responsible for processing IL-1β. IL-1β mRNA 
and protein were both increased by SNAP and further amplified by morphine, whereas NLRP3 
mRNA was increased by SNAP and further amplified by morphine but NLRP3 protein was only 
increased by SNAP alone and was not further amplified by morphine. These results implied that 
increased processing of IL-1β by the NLRP3 inflammasome may be partially responsible for the 
exaggerated IL-β release induced by morphine, but that there are likely other mechanisms 
involved and they need to be further explored. Taken together, this complete set of studies 
suggests that administering opioids after traumatic injury can be detrimental to long-term health 
and recovery, and that mechanisms underlying this phenomenon include amplification of glial 
activation, TLR4, and IL-1β. 
 Central neuropathic pain is extremely difficult to treat and the underlying mechanisms are 
multi-faceted and complex. The failure of treatments that only target neuronal cells suggests that 
there are other cell types that are critically involved, and it is important to develop therapies that 
target more than just neurons. The current series of studies provide evidence that blocking glial 
activation and increasing anti-inflammatory mediators attenuate central neuropathic pain and 
neuroinflammation, while amplifying glial activation and proinflammatory mediators can 
potentiate central neuropathic pain and neuroinflammation. It is important to recognize this 
dichotomy, and by manipulating glia and other immune cells it may be possible to develop 
better, more efficacious therapies and fundamentally change the way neuropathic pain is treated. 
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The clinical utility of administering glial activation inhibitors for central 
neuropathic pain 
A significant issue in the chronic pain field is the failure of the majority of available 
treatments in the clinical population. Although there are likely many different complex reasons 
for this, one reason could be that most of the current neuropathic pain treatments that are 
clinically available target neurons. The studies presented in this dissertation provide strong 
evidence that targeting glia and other immune cells could be a more effective way of treating 
chronic pain, and there is actual clinical evidence to support this pre-clinical data, as discussed 
below. 
In order to be considered a good candidate for clinical applications, a drug for systemic 
administration should be small, blood brain-barrier permeable, and easy to administer. All three 
of the drugs discussed in chapter II (propentofylline (PPF), ibudilast, and (+)-naltrexone) fit 
these criteria and all three have been tested clinically. PPF has been previously tested in clinical 
trials for Alzheimer’s and vascular dementia,164, 239 schizophrenia,272 and multiple sclerosis.307 
Although the results of these trials were not definitive, they did suggest improvements with PPF 
compared to controls. More recently, PPF was tested in a clinical trial to treat post herpetic 
neuralgia (PHN). Nearly half of PHN patients fail to respond or have intolerable side effects to 
neuronally-based medications including opioids, tricyclic anti-depressants, gabapentin, and 
pregabalin.
74, 354
 Unfortunately, the clinical trial using PPF for controlling PHN failed. However, 
there were major problems with how the trial was run. First, many of the side effects that patients 
experienced would not have required PPF to reach the CNS, therefore there are questions about 
whether the dosing was correct. Next, it is known that food intake prevents absorption of PPF, 
and the patients in this trial were not on food restrictions.
342
 Finally, patients were only treated 
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with PPF for four weeks,
175
 whereas most other clinical studies of chronic pain medications treat 
for at least six weeks.
108, 266, 331
 Chapter II discusses multiple examples of drugs failing with only 
a few administrations, but are then successful if given for a longer duration. If PPF was given for 
longer in the PHN clinical trial, it might have reached significance. Similar to PPF, ibudilast is 
also used clinically in a variety of applications including allergic rhinitis
194
 and conjunctivitis,
269
 
chronic obstructive pulmonary disease,
10
 and asthma.
155
   It is also currently being tested in 
clinical trials for migraine and in MS, where it was discovered to have neuroprotective effects 
and potentially anti-inflammatory effects.
13
 Furthermore, ibudilast has been tested (both single 
and multiple dosing) in healthy volunteers and did not cause any serious adverse effects, had few 
side effects, and was well tolerated.
263
 Unlike PPF and ibudilast, the (+)-isomer of naltrexone has 
not been clinically tested. However, the (-)-isomer of naltrexone was approved by the FDA to 
treat opioid addiction in 1984 and was run through clinical trials and approved to treat alcohol 
use disorders in 1994.
229, 334, 335
 In addition, the Department of Defense has funded Xalud 
Therapeutics to move (+)-naltrexone to Investigational New Drug status, positioning it for future 
clinical trials in drug abuse and neuropathic pain. Moving to clinical trials for SCI neuropathic 
pain will be facilitated by Xalud Therapeutics’ development of (+)-naltrexone toward FDA 
Investigational New Drug status, with all of the requisite toxicology, scale-up manufacturing, 
stability testing, etc. involved. Taken together, there is promising clinical data to back up the pre-
clinical data discussed in chapter II suggesting that these glial activation inhibitors could be the 
future for treating central neuropathic pain.    
Adenosine itself is antinociceptive in humans,
274
 but is problematic in that it can 
dramatically reduce heart rate and cause undesirable side effects.
369
 However, adenosine agonists 
are now being recognized as good candidates for treating neuropathic pain in addition to other 
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disorders including cancer, arthritis, and diabetes.
64, 258, 333
 Although there are also clinical 
antagonists for each of the adenosine receptor types, they will not be discussed here as there is 
little evidence of their efficacy in CNS disorders. A1 agonists are the most difficult to develop 
because of off-target effects, receptor desensitization, and decreased heart rate.
15, 158
 Multiple 
pain clinical trials using A1R agonists have been discontinued, likely due to these issues.
218
 One 
study using the A1R agonist GR79236 in migraine patients was successful with only minor 
adverse effects;
102
 however, the use of partial agonists and allosteric enhancers seems to be more 
promising, especially for pain. Allosteric enhancers have attracted attention in recent years given 
that they bind receptors at distinctly different sites from the primary ligand site (active site), and 
can induce a conformational change in the receptor that changes the potency or affinity of the 
primary ligand for the receptor.
282
 Partial agonists are being tested clinically for treating type II 
diabetes,
65, 158
 and there is an A1R allosteric enhancer, T-62, that was in clinical trials for PHN 
but was terminated due to transient increases in liver enzymes in some patients.
12, 369
 Perhaps the 
best candidate adenosine receptor for developing pain therapeutics is the A2AR.There was one 
clinical trial completed by Biovitrum using the orally administered A2AR agonist BVT.115959 to 
treat diabetic neuropathic pain.
369
 Although parkinsonian-like symptoms and vasodialtory effects 
of adenosine receptor activation have been linked to the A2R when administered peripherally,
146
 
the drug was well-tolerated (three doses/day for four weeks), and there was a statistically 
significant slight improvement in pain symptoms, although the mechanism of action was 
assumed to be more peripherally rather than centrally mediated. Part of our hypothesis regarding 
the anti-inflammatory effects of A2AR agonists is that they increase levels of IL-10. A current 
clinical study found that in cultured lymphocytes from rheumatoid arthritis patients, CGS21680 
dose-dependently increased IL-10,
333
 which lends support to our hypothesis. Importantly, 
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CGS21680 did not affect cell viability and did not have cytotoxic effects on these human 
lymphocytes,
333
 suggesting that it could be well-tolerated in pain patients. The other A2AR 
agonist studied in chapter III, ATL313, is also being developed for clinical use by Clinical Data 
for acute inflammatory pain and ophthalmic disease.
218
 In addition to the studies discussed in 
chapter III, we have tested ATL313 in a variety of pain models, and a single intrathecal injection 
reverses pain in chronic constriction injury (CCI), spinal nerve ligation (SNL), and sciatic 
inflammatory neuropathy (SIN).
192
 Of note, ATL313 does not cross the blood brain barrier, but it 
does reverses zymosan-induced allodynia when administered directly over the sciatic nerve in 
the SIN model, suggesting that peripheral administration could have some therapeutic effects 
(Ellis, unpub. obs.). Although the mechanisms underlying A2AR agonist-induced pain reversal 
are still poorly understood, we have evidence that PKA/PKC are involved,
192
 which could 
provide more therapeutic targets as there are multiple protein kinase inhibitors in clinical 
development for treating pain.
4, 52, 105, 271
 Although there are multiple examples of successful 
preclinical studies using A2BR agonists for pain,
192
 atherosclerosis,
218
 and diabetes,
151
 there are 
currently none in clinical trials. Interestingly, A2BR activation increases cAMP similar to A2AR 
activation, suggesting that development of clinical agonists would be worthwhile. Like A2BR 
agonists, there are currently no A3R agonists in clinical trials. However, there is preclinical 
evidence that A3R agonists decrease neuropathic pain
44
 and reduce ischemic brain injury,
42
 
indicating that these agonists could be successful in future clinical trials. Although there are clear 
difficulties in developing adenosine agonists, the preclinical evidence here and in chapter III as 
well as the clinical data suggests that adenosine agonists, especially A2AR agonists, should be 
pursued at least for treating chronic pain if not the other central disorders discussed. 
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As discussed in chapter IV, there are very few clinical studies on the deleterious effects 
of administering opioids after trauma, and the majority of the studies actually examine post-
operative pain rather than trauma pain (ie. SCI pain).
123, 328
 It is critical that more clinical studies 
designed specifically to examine the deleterious effects of administering opioids after 
trauma/surgery are undertaken because opioids are almost universally used as a first line 
treatment for trauma patients and for most surgical procedures in general. It is also imperative 
that we develop alternative compounds. Since opioids truly are the best analgesic available, it 
would be advantageous to be able to administer a drug along with the opioid to still allow for the 
analgesic effects while reducing the negative effects. (+)-Naltrexone would be an excellent 
candidate, and we are currently funded by the Department of Defense to explore these 
possibilities with (+)-naltrexone on enhancing morphine analgesia, decreasing amplification of 
pain, enhancing motor recovery, and decreasing injury lesion size and constipation. If (+)-
naltrexone is successful in ameliorating some of these deleterious effects, it could change the 
way military personnel and civilians alike are treated after traumatic injury. Of note from chapter 
IV, morphine did not amplify pain or inflammation in naïve rats, suggesting that 
trauma/inflammation must already be present at the time of opioid administration in order to see 
the deleterious effects. This is important clinically because we would not expect to see these 
negative effects in healthy individuals who take opioids recreationally or acutely for a single 
procedure. The clinical implications of the deleterious effects of opioid administration are too 
large to ignore and more research needs to be done in order to elucidate the mechanisms and 
develop alternatives.  
Chronic pain affects millions of people and is very complex and has been historically 
extremely difficult to treat. We now know that neuropathic pain is not just a product of neuronal 
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hyperexcitability, but is also the result of glial activation and subsequent release of 
proinflammatory substances. The evidence presented in this dissertation will hopefully help to 
guide the development of glially-targeted therapies in order to offer true relief to those suffering 
from chronic pain disorders.  
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